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THE NOVEL DRUG DELIVERY
1
 
 The aim of the Novel drug delivery system is to provide a therapeutic amount 
of drug to the appropriate site in the body to accomplish promptly and then maintain 
the desired drug concentration. The drug delivery system should deliver drug in rate 
controlled manner in the body over a specific term of treatment. 
 This idealized objective switches to the two main aspects they are as follows 
 I. Spatial drug delivery 
  Targeting a drug to a particular organ or tissue. 
 II.Temporal drug delivery 
  Drug delivery rate to target tissue is controlled. 
The prime areas of research and development for NDDS are 
 1. Liposomes 
 2. Niosomes 
 3. Nanoparticles 
 4. Transdermal drug delivery 
 5. Implants 
 6. Oral system 
 7. Microencapsulation/ Microcapsules 
Novel drug delivery system can be divided into 2 systems 
 a. Sustained release drug delivery system 
 b. Controlled release drug delivery system 
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Fig No.1.1 Plasma concentration Vs. Time curve 
Sustained release drug delivery system 
 It is a Pharmaceutical dosage form to retard the release of a therapeutic effect 
such that it looks in the systematic circulation is delayed and the plasma profile is 
sustained in duration. The onset of its Pharmaceutical action is often slow and the 
duration of its therapeutic effect is sustained.  
 Controlled release drug delivery system 
 This system has a meaning that goes beyond the scope of sustained drug 
action it manifests a predictability and reproducibility in the drug release kinetics. The 
release of drug from a controlled release drug delivery system gains at a rate profile 
that is not only predictable kinetically but also reproduced from one unit to another. 
I. Rate pre-programmed drug delivery system 
II. Activation- modulated drug delivery system  
III. Feed – back regulated drug delivery system 
IV. Site- targeting drug delivery system 
Merits of Controlled drug delivery system
1
 
 Improved patient convenience and compliance. 
 Reduction in fluctuation in steady state levels. 
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 Increased safety margin of high potency drugs due to better control of plasma 
levels. 
 Maximum utilization of drug enabling reduction in total amount of dose 
administered. 
 Reduced in health care cost through 
 Improved therapy. 
 Shorter treatment period. 
 Lower frequency of dosing. 
 Reduction in personnel time to dispense, administer and 
monitor patients. 
Demerits of CDDS
1
 
1. Decreased systemic availability in comparison to immediate release 
conventional dosage forms, which may be due to  
i. Incomplete release 
ii. Increased first-pass metabolism 
iii. Increased instability 
iv. Insufficient residence time for complete release 
v. Site specific absorption 
v. pH dependent stability etc.  
2. Poor in-vitro – in- vivo correlation. 
3. Possibility of dose dumping due to food, physiologic or formulation 
variables or chewing or grinding of oral formulations by the patient and thus, 
increased risk of toxicity.  
4. Retrieval of drug is difficult in case of toxicity, poisoning or 
hypersensitivity reactions. 
5. Reduced potential for dosage adjustment of drugs normally administered in 
varying strengths.    
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ORAL CONTROLLED DRUG DELIVERY SYSTEM
2
 
 Oral route has been the commonly adopted and most convenient route for the 
drug delivery. Oral route of administration has been received more attention in the 
pharmaceutical field because of the more flexibility in the designing of dosage form 
than drug delivery design for the other routes. 
  In last two decades the drug delivery technology has been developed rapidly 
and many novel oral drug delivery systems have been invented. Despite tablets, 
capsules, suspension, emulsion and solution, they are more superior to the 
conventional oral formulation. Because of their clinical advantages over immediate 
release pharmaceutical products containing the same drugs, sustained release system 
and controlled release drug delivery systems are developed which are 
interchangeable.  
 Some oral controlled drug delivery formulations 
 Osmotic tablets 
 Mucoadhesive tablets 
 Matrix tablets 
 Film coated tablets 
 Enteric coated tablets 
 Swellable tablets 
 Floating capsules 
 Microgranules and spheroids 
 Beads 
 Pellets 
 Microcapsules and microspheres 
DISCOVERY OF MICROSPONGE DRUG DELIVERY
3
 
In the current years the development of new drugs is not sufficient for the drug 
treatment. But it also involves the development of suitable drug delivery system at site 
of action. The in-vivo fate of the drug is not only determined by the properties of the 
drug, but it is also determined by the carrier system, which permits a controlled and 
localized release of the active drug according to the specific need of the therapy. The 
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biggest challenge up to date is to control the delivery rate of the medicaments by 
various modern technologies met by extensive research. 
However, TDS is not practical for delivery of materials whose final target is the 
skin itself. The controlled release of drug from the formulation into the epidermis 
such that the drug remains primarily localized with only a restricted amount entering 
the systemic circulation, is a means of controlling side-effects. Thus, the need exists 
for delivery systems to maximize the period of time that an active ingredient is 
present, either on the skin surface or within the epidermis while minimizing its 
transdermal penetration into the body. Another potential problem in topical delivery 
of drugs relates to uncontrolled evaporation of the active ingredient, unpleasant odour, 
the use of unaesthetic vehicles which may be greasy, sticky and may cause 
discolorations, since this can result in the lack of patient compliance. 
Carrier technology is the potential solution to these challenges. Microparticles 
and nanoparticles have been increasingly researched to achieve targeted and sustained 
release of drugs. These include microspheres, liposomes, and nanoparticles etc. which 
alter the absorption and release characteristics of the drug. Microspheres are unable to 
control the release rate of drug from itself. Once the outer wall is ruptured the drug 
contained within microspheres will be released from it. Liposomes having demerits 
like lower drug entrapment, difficulty in preparing formulation, limited chemical 
stability and microbial stability so the preservatives are required. Solid lipid 
nanoparticles are having most of the benefits in the topical drug delivery. 
Nanomaterial can easily enter in to the systemic circulation by inhalation or ingestion, 
and possibly also via skin absorption, especially if the skin is damaged. Once in the 
blood stream, nanomaterials can be transported around the body and are taken up by 
organs and tissues including the brain, heart, liver, kidneys, spleen, bone marrow and 
nervous system. 
The microsponge-based polymeric microspheres uniquely overcome problems 
associate with above technologies. Microsponges are extremely small, inert, 
indestructible spheres that do not pass through the skin. Rather, they collect in the tiny 
nooks and crannies of the skin and slowly release the entrapped drug, as the skin 
needs it. They are designed to deliver a pharmaceutical active ingredient efficiently at 
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the minimum dose and also to enhance stability, reduce side effects and modify drug 
release.   
Microsponges are microscopic spheres capable of absorbing skin secretions, 
therefore reducing oiliness and shine from the skin. Spherical particles composed of 
clusters of even tinier spheres are capable of holding four times their weight in skin 
secretions. These products are typically presented to the consumer in conventional 
forms like creams, gels or lotions and they contain a relatively high concentration of 
active ingredients. Recently their use is also being investigated for oral drug delivery. 
This article provides concise information to the various aspects of the structure, 
development, applications and future of microsponges. It is to be introductory to the 
vast amount of research that has been done and the large number of opportunities that 
exist in the field of microsponges. 
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MICROSPONGE DRUG DELIVERY SYSTEM 
 In recent years, there has been considerable emphasis given to develop novel 
Microsponge based drug delivery systems, in order to modify and control the release 
behaviour of the drugs. By incorporation into a carrier system, it is possible to alter 
the therapeutic index and duration of the activity of drugs. 
 The microsponge technology was developed by Won in 1987 and the original 
patents were assigned to Advanced Polymer Systems, Inc. Microsponges are 
polymeric delivery systems composed of porous microspheres. They are tiny sponge-
like spherical particles with a large porous surface. They may enhance stability, 
reduce side effects and modify drug release favourably. Microsponge technology has 
many favourable characteristics, which make it a versatile drug delivery vehicle.The 
Scanning Electron Microscopy of the microsponge particle reveals that its internal 
structure as the “bag of marbles”. The porosity is due to the interstitial spaces between 
the marbles. The interstitial pores can entrap many wide range of active ingredients 
such as emollients, fragrances, essential oils, sunscreens, anti-infective and anti-
inflammatory agents. These entrapped microsponges may then integrated or 
formulated into product forms, such as creams, lotions, powders, soaps, capsules and 
tablets.
4,5 
 Although the microsponge size may vary, a typical 25 μm sphere can have up 
to 250000 pores and an internal pore structure equivalent to 10 ft in length, providing 
a total pore volume of about 1 ml/g. This results in a large reservoir within each 
microsponge, which can be loaded with up to its own weight of the active agent. The 
microsponge particles themselves are too large to be absorbed into the skin and this 
adds a measure of safety to these microsponge materials. Another safety concern is 
the potential bacterial contamination of the materials entrapped in the microsponge. 
As the size of the pore diameter is smaller, the bacteria ranging from 0.007 to 0.2 μm 
cannot penetrate into the tunnel structure of the microsponges.
4
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                   Fig No.1.2   A Microsponge 
Potential features of microsponge drug delivery system
6,7
 
1. Stable over a pH range of 1 to 11. 
2. Stable  up to 130
o
C temperature. 
3. Compatible with the many of the vehicles and active ingredients. 
4. Self sterilizing as their average pore size is 0.25μm where bacteria cannot 
penetrate.  
5. Higher pay load (50 to 60%). 
6. Free flowing and cost effective. 
7. Reveal good compatibility with various vehicles and ingredients. 
8. Can absorb oil up to 6 times their weight without drying. 
9. Characterized by free flowing properties. 
 
Benefits of Microsponge Drug Delivery System
5,8
 
 
 Enhanced product performance. 
 Extended release.  
 Reduced irritation and hence improved patient Compliance.  
 Improved product elegancy.  
 Improved formulation flexibility.  
 Improved thermal, physical, and chemical stability.  
 Flexibility to develop novel product forms.  
 Non-irritating, non-mutagenic, non-allergenic and non-toxic. 
 Allows incorporation of immiscible substances. 
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Advantages of microsponges over other technologies and delivery systems 
 
Microencapsulation, liposomes and ointments 
10
 
1. Microsponges offer better control of drug release than microcapsules.        
Microcapsules cannot usually control the release rate of the API. Once the 
wall is ruptured, the API contained within the microcapsules will be 
released.  
2. Microsponges show better chemical stability, higher payload and easier 
formulation    compared with liposomes.  
3. In contrast to ointments, microsponges have the ability to absorb skin 
secretions, therefore, reducing greasiness and shine from the skin. 
Ointments are often aesthetically unappealing, greasy and sticky, resulting 
in lack of patient compliance.  
 
Topical drug delivery system 
9
 
 Conventional formulations of topical drugs are intended to work on the outer 
layers of the skin. Such products release their active ingredients upon application, 
producing a highly concentrated layer of active ingredient that is rapidly absorbed. 
When compared to conventional formulation, the Microsponge system can prevent 
excessive accumulation of ingredients within the epidermis and the dermis. 
Potentially, the Microsponge system can reduce significantly the irritation of effective 
drugs without reducing their efficacy. Microsponges are extremely small, inert, 
indestructible spheres that do not pass through the skin. Rather, they collect in the tiny 
nooks and crannies of the skin and slowly release the entrapped drug, as the skin 
needs it. 
Oral drug delivery 
10
 
1. Preserve the active ingredients within a protected environment and offer 
oral controlled delivery to the lower part of the GIT.  
2. Microsponge systems improve the solubility of poorly soluble drugs by 
entrapping these drugs in their porous structure.  
3. As the porous structure of the microsponge is very small in size, the drugs 
entrapped will be reduced to microscopic particles with higher surface area, and 
consequently improved rate of solubilisation.  
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4. Maximize the amount of drugs to be absorbed, as the time it takes the 
microsponge system to pass through the intestine is considerably increased. 
 
Properties of the actives for the entrapment into the microsponge 
3
 
i. It should be either fully miscible in monomer or capable of being made 
miscible by addition of small amount of a water immiscible solvent.  
ii. It should be water immiscible or at most only slightly soluble.  
iii.  It should be inert to monomers and should not increase the viscosity of the 
mixture during formulation.  
iv.  It should be stable when in contact with polymerization catalyst and under 
conditions of polymerization.  
v. The spherical structure of the microsponges should not collapse. 
Formulation 
3,4,9
 
  The MDS contain drug, polymer, vehicle and other additives like plasticizers 
that help to stabilize the structure.  
Various drugs used in MDS : Benzoyl peroxide, Mupirocine, Tretinoin, 
Aceclofenac, Flucinolone, acetonide,  Ketoprofen,  Paracetamol , Dicyclomine, 
Fluconazol, Hydroquinone etc.   
Polymers used:   Ethyl cellulose,  Eudragit RS 100, Polystyrene, acrylic 
polymers and PHEMA etc as they can form a microsponge “cage”. 
Vehicles used: Dichloromethane, acetone, ethanol. 
Plasticizers: Triethylcitrate, dibutyl phthlate. 
Preparation of Microsponges 
4,11
 
 Drug loading in microsponges drug delivery system is done in two ways, one 
step process or by two step process as discussed in liquid-liquid suspension 
polymerization and quasi emulsion solvent diffusion techniques which are based on 
physicochemical properties of drug to be loaded. If the drug is typically an inert non-
polar material, will create the porous structure it is called porogen. Porogen drug, 
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which neither hinders the polymerization nor become activated by it and stable to free 
radicals is entrapped with one step process.  
Liquid-Liquid Suspension Polymerization  
The  porous  microspheres  are  prepared  by  suspension  polymerization  
method  in  liquid-liquid  systems . In  their preparation,  the  monomers  are  first  
dissolved  along  with  active ingredients  in  a  suitable  solvent  solution  of  
monomer  and then  dispersed  in  the aqueous  phase,  which  consist  of  additives  
(surfactant,  suspending  agents,  etc.).  The polymerization  is  then  initiated  by  
adding  catalyst  or  by  increasing  temperature  or irradiation . 
 
 
 
Fig No.:1.3 REACTION VESSEL FOR MICROSPONGE PREPARATION BY 
LIQUID-LIQUID SUSPENSION METHOD  
The polymerization process continues the formation of a reservoir type of 
system with spherical structure. After the polymerization process the solvent is 
removed leaving the spherical structured porous microspheres, i.e., microsponges. 
The various steps involved in the preparation of microsponges are summarized below:   
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STEPS IN THE PREPARATION OF MICROSPONGES: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quasi-emulsion Solvent Diffusion  
All microsponges were prepared by a quasi-emulsion solvent diffusion method 
using an external phase containing distilled water and PVA. The internal phase 
consisted of Drug, Solvent, polymer and TEC, which was added at an amount of 20% 
of the polymer in order to facilitate the plasticity. At first, the internal phase was 
prepared and added to the external phase at room temperature. After emulsification, 
the mixture was continuously stirred for 2 hours. Then the mixture was filtered to 
separate the microsponges. The product was washed and dried by hot air oven at 40°C 
for 12 hours .    
Selection of monomer as well as combination of 
monomers 
Formation of  chain monomers as polymerization starts 
 
Folding of monomer ladder to form spherical particles 
Formation of ladders as a result of cross-linking between 
chain monomers 
Agglomeration of microspheres leads to the production of 
bunches of microspheres 
Binding of bunches to produce microsponges 
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Fig No.1.4 PREPARATION OF MICROSPONGES BY QUASI-EMULSION 
SOLVENT DIFFUSION METHOD. 
Limitations:
7
 
Both the methods usually use organic solvents as porogens, which pose an 
environmental hazard, as some may be highly inflammable, posing a safety hazard. 
Moreover, in case of the Bottom-Up approach traces of residual monomers have been 
observed, which may be toxic and hazardous to health. While the limitations seem to 
be serious, they can be easily overcome, by using proper quality control measures and 
proper washing post manufacture coupled with good standardization of the various 
processes .  
 
Drug release mechanisms 
3
 
The mentioned programmable parameters can be effectively manipulated to 
design Microsponge delivery system for the release of functional substance over a 
period of time in response to one or more external stimuli. The release mechanism of 
this system is mainly:-  
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A. Sustained or Timed Release   
In the development of a sustained release Microsponge, different physical and 
chemical parameters of the entrapped active substance such as volatility, viscosity and 
solubility will be studied while in case of polymeric microsponge pore diameter, 
volume, and resiliency of the polymeric microsponge are evaluated to give necessary 
sustained release effects. 
B. Release on Command  
Microsponges can be designed to release the given amounts of active 
ingredients over time in response to one or more external triggers.  
1. Pressure Release  
Microsponge system releases fluid or active ingredient when it is pressed or 
squeezed, thereby replenishing the level of entrapped active ingredient onto the skin. 
The amount released may also depend upon the release of the sponge and the 
resiliency of the Microsponges. 
2. Temperature Release  
The release of active ingredients from microsponges can be activated by 
temperature.  At room temperature, few entrapped active ingredients can be too 
viscous to flow suddenly from microsponges onto the skin. With increase in skin 
temperature, flow rate is also increased and therefore release is also enhanced. 
3. pH  
Triggering the pH-based release of the active can be achieved by modifying 
the coating on the microsponge. This has many applications in drug delivery. 
4. Solubility  
Microsponges loaded with water miscible ingredients like antiseptics and 
antiperspirants will release the ingredient in the presence of water. The release can 
also be activated by diffusion but taking into consideration, the partition coefficient of 
the ingredient between the microsponges and the external system. 
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Safety consideration
9
 
 Safety studies of microsponges can be established by: 
 • Eye irritation studies in rabbits. 
 • Skin irritation studies in rabbits. 
 • Mutagenicity in bacteria.  
• Oral toxicity studies in rats.  
• Allergenicity in guinea pigs. 
 Applications of microsponges
12
 
 Few applications of microsponge drug delivery system are as follows: 
 Microsponges in Oral Care Cosmetics  
An interesting application of the microsponge technology could be in oral 
cosmetics, such as to sustain the release of volatile ingredients, thus increasing the 
duration of the 'fresh feel'. Microsponges of such volatile ingredients may be easily 
incorporated in tooth pastes or mouth washes.    
 Long lasting Coloured Cosmetics:A new application for Microsponges 
 Colours entrapped in microsponges may be used in a variety of coloured 
cosmetic products such as rouge or lipsticks to make them long lasting. As stated 
above, microsponges help in uniform spreading and improving covering power. Thus, 
colored cosmetics formulated with microsponges would be highly elegant. 
 Going the natural way using a Functional Active  
Although natural actives are important consumer attractants, now the focus 
has shifted on using multifunctional natural ingredients. For example, Marinosomes®, 
liposomes made from natural antiinflammatory lipid extracts, have set a new 
paradigm in using such functional 'active excipients'. The possibility of using such 
substances for constructing a microsponge structure appears to be cost effective and 
innovative. 
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Table No.1.1: Applications along with advantages of MDDS
4
 
S.No. Application Advantages 
1. Anti-acne: Eg: Benzoyl peroxide Maintained efficacy with decreased skin 
irritation and sensitization. 
2. Anti-inflammatory: Eg. 
Hydrocortisone 
Long lasting activity with reduction of 
skin allergic response and dermatoses. 
3. Sunscreens: Long lasting product efficacy with 
improved protection against sunburns 
and sun related injuries even at elevated 
concentration and with reduced irritancy 
and sensitization. 
4. Anti-fungals: Sustained release of actives ingredient. 
5. Anti-dandruffs:Eg. Zinc pyrithione, 
selenium sulphide. 
Reduced unpleasant odour with lowered 
irritation with extended safety and 
efficacy. 
6. Antipruritics: Extended and improved activity. 
7. Skin depigmenting: Eg: 
Hydroquinone 
Improved stabilization against oxidation 
with improved efficacy and aesthetic 
agents appeal. 
8. Rubefacients: Prolonged activity with reduced irritancy 
greasiness and odour. 
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Table No.:1.2   Examples of microsponge drug delivery with their formulations
4
 
MDS Drug Disease 
Gels Benzoyl  peroxide Anti- acne treatment 
Diclofenac sodium Inflammation 
Terbinafine HCl Anti-fungal 
Hydroxyzine HCl 
 
Urticaria and atopic 
dermatitis 
Mupirocin Antibacterical activity 
Creams Hydroquinone and retinol Melanoma 
Implants Poly(DL- lactic-co-glycolic 
acid) 
Sin tissue engineering 
Lotions Benzoyl peroxide Anti-acne treatment 
Tablets Ketoprofen Musculoskeletal pain 
Paracetamol 
 
Colon targeting 
Meloxicam Arthritis 
Others Benzoyl peroxide Anti- acne treatment 
Ibuprofen NSAID 
 
 
 
INTRODUCTION 
 
Department of Pharmaceutics, Madras Medical College Page 18 
 
Table No.:1.3  Marketed formulations of microsponges
13
 
Product name Advantages Company 
Carac cream, 
0.5% 
Carac cream contains 0.5% 
fluoruracil with 0.35% being 
incorporated into a patented porous 
microsphere(Microsponge) 
composed of methyl methacrylate 
cross polymer and dimethicone 
Dermik laboratories, Inc. 
Berwyn,PA 19312 USA 
Retinol cream The retinol molecule is kept in the 
microsponge system to protect te 
potency of vitamin A. This helps to 
maximize the retinol dosage, 
wthile reducing the possibility of 
irritation. Retinol is a topical 
vitamin A derivative, which helps 
maintain healthy skin, hair and 
mucous membranes. 
Biomedic 
Retin- A-Micro 0.1 and 0.04%  tretinoin entraped 
in MDS,  for topical treatment of 
acne vulgaris. This formulation 
uses patented methyl methcrylated 
cross polymer porous microspheres 
Ortho-Mc Neil 
Pharmaceutical, Inc. 
EpinQuin micro The Microsponge system entrap 
hydroquinone and retinol. The 
microsponges release these 
ingredients into the skin gradually 
throughout the day, which may 
minimize skin irritation. 
Skin Medica Inc. 
Oil control 
lotion 
Feature light lotion microsponges 
that absorb oil on the skin’s 
surface during the day, for a matte 
finish. Eliminate shine for hours 
with this feature- weight lotion. 
Fountain cosmetics 
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Sports cream 
RS and XS  
Topical analgesic, anti-
inflammatory and counter irritant 
actives in a MDS for the 
management of musculosketal 
conditions. 
Embil Pharmaceutical Co. 
Ltd. 
Line Eliminator 
dual retinol 
facial treatment  
Light weight cream with a retinol 
in MDS, delivers both immediate 
and time released wrinkle fighting 
action. 
Avon 
Retinol 15 night 
cream 
A night time treatment with 
microsponge technology using a 
stabilize formula of pure Retinol 
and vitamin A. 
Sothys 
Salicylic peel 
20 
Deep BHA peeling agent for 
salicyclic acid 20% microsponge 
technology. Excellent exfoliations 
and stimulation of skin for more 
resistant skin types or for faster 
results. 
Biophora 
Salicylic peel 
30 
Deep BHA peeling agent for 
salicyclic acid 30% microsponge 
technology. Excellent exfoliations 
and stimulation of skin for more 
resistant skin types or for faster 
results. 
Biomedic 
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Table No.1.4: Patents filed related to microsponges
9 
Patent No. Inventors Publications Date 
US4690825 Won. Richard 1987 
US4863856 Dean RC Jr et al. 1989 
US5292512 Schaefer et al 1989 
US5135740 Katz et al 1992 
US5679374 Fanchon; Chantal et al 1994 
US5316774 Eury, Robert P et al 1994 
US5725869 Lo; Ray J.R 1996 
US6395300 Straub et al 1999 
US6211250 Tomlinson et al 2001 
US20030232091 Shefer et al 2005 
US20040247632 Cattaneo, M 2004 
US20050271702 Wright,Steven G et al 2005 
 
Recent advances in microsponge drug delivery 
9
 
Various advances were made by modifying the methods to form nanosponges, 
nanoferrosponges and porous microbeads.  
β-CD nanosponges were also developed that can be used for hydrophobic as 
well as hydrophilic drugs, in contrast to polymeric micro or nanosponges. These 
advanced systems were studied for oral administration of dexamethasone, 
flurbiprofen, doxorubicin hydrochloride, itraconazole and serum albumin as model 
drug. These nanosponges were developed by cross-linking the β-CD molecule by re-
acting the β-CD with diphenyl carbonate. Some researchers also observed the 
nanosponges as good carrier for the delivery of gases. Researchers also observed that 
incorporating a cytotoxic in a nanosponge carrier system can increase the potency of 
the drug suggesting that these carriers can be potentially used for targeting the 
cancerous cells. 
 Nanoferrosponge, a novel approach constituted the self-performing carriers 
having better penetration to the targeted site due to the external magnetic trigger 
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which enforces the carriers to penetrate to the deeper tissue and then causing the 
removal of magnetic material from the particle leaving a porous system. 
Due to the improved characteristics of porous microspheres, process was 
developed to produce the porous micro beads. This method (High Internal Phase 
Emulsion, HIPE) consisted of the monomer containing continuous oil phase, cross 
linking agent and aqueous internal phase. They also observed an improved stability of 
RNA and the relatively effective encapsulation process of siRNA. The approach could 
lead to novel therapeutic routes for siRNA delivery. 
Future prospects  
3
 
Microsponge drug delivery system holds a promising opportunity in various 
pharmaceutical applications in the upcoming future as it has unique properties like 
enhanced product performance and elegancy, extended release, improved drug release 
profile, reduced irritation, improved physical, chemical and thermal stability which 
makes it flexible to develop novel product forms. The real challenge in future: 
 The development of the delivery system for the oral peptide delivery 
by varying ratio of polymers.  
 The use of bioerodible and biodegradable polymers for the drug 
delivery is enabling it for the safe delivery of the active material.  
 As these porous systems have also been studied for the drug delivery 
through pulmonary  route which shows that these system can show 
effective drug release even in the scarce of the dissolution fluid thus 
colon is an effective site for targeting for drug release.   
 These carriers also require to be developed for alternative drug 
administration routes like parenteral and pulmonary route.  
 These particles can also be used as the cell culture media and thus can 
also be employed for stem cell culture and cellular regeneration in the 
body.  
 Due to their elegance, these carrier systems have also found their 
application in cosmetics.  
These developments enabled researchers to utilize them variably. These 
novelties in formulation also open new ways for drug deliver. 
LITERATURE REVIEW 
 
Department of Pharmaceutics, Madras Medical College Page 22 
 
Literature related to MDS 
1. Vikas Jain et al.16 formulated Paracetamol loaded Eudragit based 
microsponges using quasi-emulsion solvent diffusion method. Shape and 
surface morphology of the microsponges were examined using SEM. The 
formulations were subjected to in-vitro release studies and the results were 
evaluated kinetically and statistically. The in-vitro release data showed a 
biphasic pattern with an initial burst effect. The release kinetics showed that 
the data followed higuchi model and the main mechanism of drug release was 
diffusion. 
 
2. Vikas Jain et al.17 developed a prolonged MDS system containing 
Dicyclomine. Dicyclomine loaded Eudragit based microsponges were 
prepared using quasi-emulsion solvent diffusion method. Increase in drug: 
polymer ratio resulted in a reduction in the release rate of the drug from the 
microsponges. Kinetic analysis showed that the main mechanism of drug 
release was by higuchi matrix-controlled diffusion. The unique 
compressibility of microsponges can be applied to achieve effective local 
action. 
 
3. Anil kumar et al.18  prepared Fenoprofen microsponges by Quasi-emulsion 
solvent diffusion method. Four different drug-polymer ratio was prepared and 
performed experimental design by changing concentration of solvent. 
Prepared microsponges were formulated as tablets and compressed using 
chitosin: HPMC mixture for colon targeting. Optimised microsponge 
formulations were subjected to in-vitro dissolution studies and found to 
modify the release rate. The colon specific tablets release the drug at 8
th
 hour 
due to addition of  ß- glycosidase and continued upto 18
th
 hour. 
 
4. Riyaz Ali et al.19 developed Domperidone for augmented gastroparesis 
therapy using quasi emulsion solvent diffusion method using Eudragit RS 100 
with various drug- polymer ratios. Developed systems was more proficient to 
give extended dug release, superior in contrast to conventional marketed 
formulation. Characterization techniques were done and microsponges were 
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loaded in capsules followed by in-vitro drug release study.1:2 drug-polymer 
ratio showed extended release when compared to conventional marketed 
formulation Domstal. 
 
5. Karthika et al.20  prepared microsponges containing Lornoxicam and Eudragit 
RS 100 were by quasi emulsion solvent diffusion method. The effects of drug 
to polymer ratios on physical characteristics of the microsponges were 
investigated. Compatibility of drug with adjuncts was studied by FT-IR. 
Production yield, loading efficiency, particle size analysis, surface 
morphology and in-vitro release studies were carried out. The microsponges 
were compressed into tablets. The effects of different stirring rates, amount of 
solvent, amount of emulsifier used on the physical characteristics of the 
microsponges were investigated. In-vitro dissolution studies were done on all 
formulations and the results were kinetically evaluated and the release rate of 
Lornoxicam was found to be modified.  
 
6. Sonali et al.21 developed Prednisolone loaded microsponges for colon specific 
drug delivery by using quasi-emulsion solvent diffusion method with Eudragit 
RS 100 as polymer. Evaluation like FTIR, SEM, particle size, production 
yield, drug entrapment efficiency were examined. In-vitro dissolution studies 
showed modified release for 8 hours and best fitted a zero order kinetic model. 
Plasma drug concentration of drug was also studied for optimized formulation 
and Cmax, tmax and AUC was also observed. 
 
7. Rashmi et al.22 formulated curcumin microsponges for colon specific drug 
delivery by Quasi-emulsion solvent diffusion method using 3
2 
full factorial 
design. Prepared microsponges were optimized in order to analyze the effects 
of independent variables (volume of ethanol and  Eudragit L100) on the 
encapsulation efficiency ,particle size, and drug release. The optimized 
formulation was subjected to in-vivo study using acetic acid induced colitis 
model in rats. Release studies revealed that microsponges prevented the 
premature release of curcumin in upper GIT and specifically released the drug 
at colonic pH. 
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8. Ramani Gade et al.23 developed Hydroxyzine hydrochloride microsponges 
using polymer methocel 10000 cps  and in combination with Eudragit –S 100, 
Eudragit-L 100, Eudragit-RL 100 and Eudragit-RS 100. These are prepared by 
oil in oil emulsion solvent diffusion method using acetone as dispersing 
solvent and liquid paraffin as the continuous medium. Compatibility of the 
drug with adjuncts was studied by FT-IR. Production yield, loading efficiency, 
particle size analysis, surface morphology and in-vitro release studies were 
carried out. The microsponge tablet formulation, F11 showed controlled 
release of hydroxyzine hydrochloride for 12hrs. 
 
9. Shah Harsh et al.24  prepared Aceclofenac microsponges using polymers like 
Ethyl cellulose, Eudragit RS 100, Eudragit S100 and Eudragit RL 100 in 
different concentrations. Evaluations were performed and optimized batch was 
formulated as colon targeting tablet. In- vitro dissolution study showed 
controlled release upto 24 hours. This technique have enhanced solubility, 
flow properties and compression characteristics. 
 
10. Riyaz Ali et al.25 formulated and evaluated gel containing microsponges of 
Diclofenac diethylamine by using eudragit RS 100 with varied drug- polymer 
ratios. They were characterized by SEM,DSC, FTIR, XRPD and particle size 
analysis and evaluated for morphology, drug loading in-vitro drug release and 
ex- vivo diffusion as well. 
 
11. John I D’souza et al.26 formulated Fluocinolone Aceonide microporous  
microparticles to control the release of drug to the skin. Microsponges were 
prepared by quasi emulsion solvent diffusion method. Production yield, 
loading efficiency, particle size analysis and surface morphology were 
performed. Surface morphology by SEM revealed microporous nature of 
microsponges. Drug release was observed controlled with comparative anti- 
inflammatory active with the gels containing free drug. 
 
LITERATURE REVIEW 
 
Department of Pharmaceutics, Madras Medical College Page 25 
 
12. Markand Mehta et al.27 prepared Clotrimazole microsponge by emulsion 
solvent diffusion technique by using Ethyl cellulose , HPMC K4M, Carbopol 
934, Eudragit RS 100, Eudragit S 100, Eudragit RL 100 and evaluated for % 
practical yield, % loading efficiency and in- vitro drug release study. The drug 
release data of optimized batch were fitted into different kinetic models which 
show that the drug release from gel formulations follows zero order release. 
So encapsulation of clotrimazole into microsponge would modify the release 
rate and also reduce side effects. 
 
13. Hamid Hussain et al.28  developed gel loaded microsponges of  diclofenac 
sodium by quasi emulsion technique employing ethyl cellulose as polymer. 
Compatibility of drug-excipients was done by FTIR. SEM, particle size, 
production yield, drug entrapment efficiency were examined. Prepared 
microsponge was dispersed in carbopol gel base for controlled delivery to the 
skin. Spreadility, pH determination, in-vitro diffusion study using KC cell 
were performed. 
 
14. Makwana Rajshree et al.29 carried Photostability enhancement of  
Miconazole nitrate by ethyl cellulose microsponges formulation using Quasi-
emulsion technique. The prepared microsponges were subjected to in-vitro 
dissolution studies, FTIR and DSC.  Microsponge showed higher 
photostability as compared to plain drug and other physical mixture. 
 
15. Ramadevi et al.30 formulated Itraconazole loaded microsponges using 
Eudragit RS 100 by quasi emulsion solvent diffusion method. The 
formulations were evaluated for % loading efficiency, drug entrapment 
efficiency, morphology, surface topography by SEM, in-vitro release, release 
kinetics, pore diameter were measured. Release rate was found to be 
controlled for 6 hours. 
 
16. Mahajan Aniruddha G et al.31 prepared controlled release formulation of  
Indomethacin microsponges by quasi emulsion solvent diffusion method. 
Microsponges were evaluated by micromeritic properties, drug content, 
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encapsulation efficiency and particle size. In- vitro dissolution study indicated 
that the release of Indomethacin varied according to the concentration of 
matrix forming polymer. 
 
17. Ravi et al.32 prepared  Erythromycin microsponges using quasi emulsion 
solvent diffusion method. Erythromycin microsponges were then incorporated 
into a Carbopol-940 gel prepared by hydrogel technique for release studies. 
The best formulation was found to be stable at room temperature for 3 months. 
Thus it was concluded that erythromycin can be formulated as microsponge 
gel that can release the drug upto 8hrs with reduced side effects.   
 
18. Mohana Kumar et al.33 prepared Mupirocin microsponges  using an 
emulsion solvent diffusion method. FT-IR and SEM was used to study the 
shape and morphology of microsponges. Mupirocin microsponges were then 
incorporated into a vanishing cream base for release studies. It was shown that 
the drug: polymer ratio, stirring rate, volume of external and internal phase 
influenced the particle size and drug release behavior of microsponges. The 
results showed that an increase in the ratio of the drug: polymer resulted in a 
reduction in the release rate of Mupirocin from microsponges. Kinetic analysis 
showed that the main mechanism of drug release was by Higuchi matrix- 
controlled diffusion. 
 
19. Swetha A et al.34 formulated microsponges containing Ethylcellulose and 
Eudragit RS 100 by quasi emulsion solvent diffusion method using Etodolac. 
The effects of different drug to polymer ratios on physical characteristics of 
microsponges were investigated. Surface morphology, particle size and pore 
structure of the microsponges were examined. In- vitro dissolution study 
showed that the release rate of the drug has been modified. 
 
20. P.Yadav et al.35 prepared Microsponge loaded controlled release formulations 
of Acyclovir quasi emulsion solvent diffusion method. They were 
characterized for particle size, production yield and entrapment efficiency. 
The range of production yield was found between 57.43% and 77.81%, 
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entrapment efficiency was found  between 68.95 % and 87.56% and particle 
size was found between 376.3 µm to 777.7 µm for different batches. Porous 
structure of microsponges was confirmed by SEM. Best optimized batch was 
incorporated in carbopol and aloe gel and lipstick base. In- vitro release 
studies using diffusion cell revealed that the drug release followed 
Korsemeyer Peppas model.  
 
21. Atmaram et al.36  formulated oxybenzone microsponges by quasi emulsion 
solvent diffusion method. The effects of Ethyl cellulose and Dichloromethane 
were optimized by the 32 factorial design. The optimized microsponges were 
dispersed into the hydrogel and further evaluated. It  showed enchanced sun 
protection factor compared to the marketed preparation with reduced irritation 
and toxicity. 
     22  Chainesh et al.
37
  prepared Fluconazole Microsponges by quasi emulsion 
solvent diffusion method using Ethyl cellulose as a polymer, polyvinyl 
alcohol, Acetone as Internal phase volume and Liquid paraffin as External 
phase volume. Optimization of Fluconazole loaded Microsponge was done by 
24 Factorial Designs.  The optimized batch of Fluconazole and Aceclofenac 
loaded Microsponge was evaluated by particle size, surface morphology and 
topography by SEM, Drug-Excipients compatibility study using FTIR. The in-
vitro drug release from the microsponges hrs was found to be extended up to 
10 Hrs. 
       23. Jaya Raj Kumar et al.
38
 prepared ketotifen microsponges with three 
different proportions of ethyl cellulose by quasi-emulsion solvent diffusion 
method. These formulations were studied for particle size and physical 
characterization. These microsponges enriched gel formulation were prepared 
by using 2  and 3 % w/w of SCMC and studied for viscosity, pH,  gel strength, 
spreadability, bioadhesive force, drug content, in-vitro release, HPLC and 
SEM analysis. The optimized formulations were able to release the drug up to 
8 hours. 
        24. Roaa et al.
39 
  developed microsponges gel of poorly soluble drug meloxicam 
microsponges  by quasi-emulsion solvent diffusion method.  The effects of 
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drug:polymer ratio, stirring time and Eudragit polymer type on the physical 
characteristics of microsponges were investigated and characterized for 
production yield, loading efficiency, particle size, surface morphology, and in-
vitro drug release from microsponges showed that the microsponge with 
Eudragit L100 polymer had optimum physical properties and enhanced the 
dissolution and release when compared with other formulae and pure drug.  
        25. Ahamed Abbas Hussain et al.
40
  prepared Ketoconazole microsponges by 
quasi emulsion solvent technique using different types of Eudragits as 
Eudragit E 100, Eudragit RS or Eudragit RL. Physicochemical interaction 
between drug and excipients as individual one, physical mixture and prepared 
microsponge has been evaluated using FTIR and DSC.  
        26. Kirti et al.
41
 prepared Diclofenac Sodium loaded Eudragit microsponges 
using quasi emulsion solvent diffusion method. Different drug: polymer ratios 
were used to formulate the microsponges. The compatibility of the drug with 
polymer was established. Surface morphology of the microsponges was 
examined using SEM.  Production yield, loading efficiency, particle size 
analysis, and in-vitro release studies were carried out. In-vitro release study 
showed that the release of drug was in controlled manner and it was increased 
with increase in drug to polymer ratio up to certain limit. 
         27. Ravi et al.
42
  prepared Erythromycin microsponges using quasi emulsion 
solvent diffusion method. The SEM and DSC studies were carried out to study 
shape, morphology of microsponges and thermal analysis respectively Thus it 
was concluded that erythromycin can be formulated as microsponge gel that 
can release the drug up to 8hrs with reduced side effects.   
Literature  related  to DCN 
 
28. Prashant S. Walke et al.
43
 enchanced solubility of  DCN by Mannitol solid 
dispersions and they were prepared in ratio 1:1, 1:3 and 1:5 by physical 
triturating, solvent evaporation and fusion method. The results showed marked 
increase in the saturation solubility and dissolution rate of DCN as compared 
to pure drug. A mannitol dispersion (1:5) prepared by  fusion method showed 
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excellent physiochemical characteristics and was described by dissolution 
kinetics. It was the best formulation in this study. 
 
29. Nitin Maski et al.
44
  studied solubility of  ßCD – DCN  inclusion complex. 
Phase solubility profile indicated that the solubility of DCN was significantly 
increased in presence of β-cyclodextrin and it was classified as AL- type, 
indicating the 1:1 stoichiometric inclusion complexes. The complexes formed 
were quite stable. The solid complexes prepared by physical mixture, co-
evaporation/solid dispersion, kneading method and precipitation method was 
characterized using Differential Scanning Calorimetry, Powder X-ray 
Diffractometry and FTIR. In-vitro study showed that the solubility and 
dissolution rate of DCN was significantly improved by complexation with β-
cyclodextrin. 
 
30. Patel Krushika et al.
45 
 studied the formulation and  evaluation of  Buccal 
tablet of the poorly soluble drug DCN. It was prepared by direct compression 
using combination of bioadhesive polymers like Carbopol 934P, HPMC , 
Sodium alginate, SCMC, HPC, PVP K 30 in different ratio. The swelling 
index of tablet increased with increasing amount of Carbopol 934P. Ethyl 
cellulose was found as optimum formulation. 
 
31. Randa et al.
46
  formulated and evaluated DCN loaded niosomes in order to 
improve dissolution hence its oral bioavailability. The formulations were 
prepared by thin film hydration. Method using different ratios of cholesterol to 
non ionic surfactants (Span 20 and 60) 1:2 and 1:3. The order of encapsulation 
efficiency niosomes indicates better release profile compared to free DCN. It 
was concluded that it is possible to enhance solubility and ultimately improve 
bioavailability of the drug by this promising approach. 
 
32. Janki Patel et al.
47
  developed a emulgel for the topical delivery of the poorly 
water soluble drug DCN. The influence of the concentration of gelling agent 
Carbopol 940(0.75%, 1%,1.25%) the concentration of both the emulsifying 
agent (2.5%,1% w/w of  mixture of Span 20 and Tween 20) and the oil phase 
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(6%,7%,8% w/w of Liquid paraffin) . The results of  in-vitro drug release 
showed that carbopol 940(1%) based emulgel gave better release. 
 
33. Deshmukh et al.
48   
 studied the improvement in solubility and dissolution rate 
of a poorly soluble drug. DCN by solid dispersion method using PVP K30 and 
HPMC E4 as carriers. Four different formulations were prepared by solvent 
evaporation method using varying drug: carrier ratios 1:1,1:2,1:3,1:4. 
Formulation containing drug: polymer ratio of 1:4 with PVP K30 showed the 
best release as compared to the Pure drug. It was concluded that PVP K30 as a 
carrier can be well utilized to improve the solubility of poorly soluble drug. 
 
34. Kotta Kranthi Kumar et al.
49 
 studied the development of formulation and 
evaluation of DCN cream which are designed to enhance the onset of action. 
The cream is designed by two phase system. The cream is formed by using the 
fusion technique. The percentage of drug content, pH, color,viscosity, 
spreadability and extrudability shown per stability study after three months, it 
gives the accurate and satisfactory results. 
 
35. Randa et al.
50
 improved solubility and dissolution rate of  DCN by solid 
dispersion method. Binary solid dispersions were made using PEG-4000 or 
PEG-6000 as carriers with varying drug: carrier ratios 1:1, 1:3 and 1:5. Also 
ternary solid dispersions were made using PEG-4000 and Pluronic F-68 at 
ratios 1:5:1, 1:5:2 and 1:5:3. Formula SD9 (1:5:3; drug: PEG-4000: Pluronic 
F-68) showed the best dissolution profile with about 44.73% of the drug being 
released in the first 5 minutes and more than 79 % of the drug being released 
in the first 15 minutes. It was concluded that combination of PEG-4000 and 
Pluronic F-68 can be well utilized. 
 
36. Richa et al.
51
  developed press coated tablet of DCN and Chlorzoxazone for 
arthritis. Drug-polymer compatibility studies were carried out by FT-IR. Core 
tablet was prepared by direct compression using Super disintegrant Sodium 
Starch Glycolate. The core tablet was compression coated with different 
quantities of coating material containing different polymers. The press coated 
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tablets coated with HPMC K4M:HPMC K100 in 64.39:35.61 ratios with 200 
mg coat weight are most likely to provide the desired delivery of DCN and 
Chlorzoxazone. 
 
37. Subramania Nainar et al
52
. investigated the use of HPMC polymer to 
formulated sustained release matrix tablets containing DCN. Prepared by wet 
granulation method. The release of drug showed non-fickian diffusion obeying 
first order kinetics.  
 
38. Dhanashri Subash Yadav et al.
53
 developed novel microcrystallization 
technique in an attempt to enhance dissolution behaviour. Acetone and water 
were used as solvent and antisolvent system respectively while PVPK30, PEG 
6000 and PXMR 188 were used as polymers in crystallization process. The 
microcrystals were characterized by XRPD SEM,FTIR and dissolution test. It 
was found that dissolution characteristics of microcrystals were significantly 
improved than that of pure DCN. Also XRPD, FTIR reflected altered 
molecular arrangement in their structure. 
 
39. Veren wally  et al.
54
  hypothesized that a topical formulation of DCN 1% DCN 
cream for one armpit and placebo for the other. The number of blisters was 
reduced significantly below the initial level even during withdrawal in four 
patients. 
 
Literature related to analysis of  DCN  
 
40. Chitlange et al.
55
  described a stability-indicating HPTLC method for analysis 
of DCN in bulk and pharmaceutical dosage form. Precoated silica gel 60 F254 
plate was used as stationary phase. The separation was carried out using 
Toluene: Isopropyl alcohol: Ammonia   (4.6:4.6:0.8 %v/v/v) as mobile phase. 
The Rf value for the drug was found to be 0.30±0.01. The linearity was 
obtained in the range 100-350ng/band (r2 = 0.9909). The method was 
validated as per ICH guidelines. DCN was subjected to forced degradation by 
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acid, alkali, oxidation and dry heat. The degradation products were well 
resolved from the pure drug with significantly different Rf values.  
 
41. Sanjay et al. 
56
  developed two simple and sensitive colorimetric methods for 
quantitative estimation of Diacerin from Pharmaceutical Capsule dosage form. 
Developed methods are based on the formation of Chloroform extractable ion 
pair coloured complex of drug with Orange II (Method A) and Tropoelin 
(Method B). The complex formed in method A and B showed maximum 
absorbance at 435. Linearity was obeyed in concentration range of 50-350 
µgm/ml and 50250 µgm/ml of Diacerein for method A and B respectively. 
The results of analysis were validated statistically and by recovery studies. 
 
42. Pulla reddy et al. 
57
  performed chromatographic analysis on Agilent, Zebra 
C18 reversed phase column with mobile phase consisting Ammonium acetate: 
acetonitrile in the ratio 60:40% v/v, at a flow rate of 1.0 ml/min and eluents 
monitored at 267nm. The method was validated for linearity, accuracy, 
precision, robustness and application for assay as per International Conference 
on Harmonization (ICH) guidelines. 
 
43. Appala raju et al. 
58
 developed reverse phase HPLC method for the estimation 
of DCN in tablet dosage form. An Inertsil ODS-3V analytical column (250 x 
4.6 mm, 5 μm partical size) with mobile phase consisting of mixture of buffer 
0.03M Potassium Dihydrogen Orthophosphate in water and pH adjusted to 
3.20 with Ortho-phosphoric acid and Acetonitrile in the gradient program was 
used. The method was validated by determining its accuracy, precision and 
linearity. The results of the study showed that the proposed RP-HPLC method 
is simple, rapid, precise and accurate, which is useful for the routine 
determination of DCN in bulk drug and in its pharmaceutical tablet dosage 
form.  
 
44. Selvam et al.
59
 developed a novel, simple, rapid and sensitive 
spectrophotometric method for the estimation of DCN in capsule dosage form. 
In this method Acetonitrile was used as solvent. The maximum absorption was 
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found to be 255nm. Beer’s law was obeyed in the concentration range of 2-
10µg/mL. The method is found to be rapid, precise and accurate and can be 
employed in the laboratory for the routine estimation of the drug. 
 
45. Vijayageetha et a.
60 
developed simultaneous spectrophotometric determination 
of DCN and Aceclofenac tablets by partial least squares and principal 
component regression methods do not require any prior graphical treatment of 
the overlapping spectra of two drugs in the mixture. Chemometric methods 
were found satisfactorily for determination. 
 
46.  Narendra kumar et al.
61
   developed a simple, rapid and accurate colorimetric 
method for the estimation of DCN in bulk and pharmaceutical dosage forms, 
method are based on pink colored complex formation between DCN with 
sodium hydroxide which shows maximum absorbance at 514 nm.  The 
linearity was found to be 10-50µg/ml. The developed method was found to be 
precise and accurate form the statistical validation of the analysis. 
 
47. Khemchand et al.
62
  developed for the quantitative estimation of DCN from 
Pharmaceutical Capsule dosage form based on the solubility of DCN in 
Phosphate buffer having pH 6.8. The drug showed maximum absorbance at 
258 nm. Linearity was obeyed in concentration range of 5-30 µg/ml. The 
results of analysis were validated statistically and by recovery studies.   
 
48. Gurupaddaya et al.
63
 developed a spectrophotometric method for 
determination of DCN in pure form and pharmaceutical formulations based on 
the reaction of carboxylic acid group of the drug with a mixture of potassium 
iodate (KIO3) and potassium iodide (KI) in aqueous medium at room 
temperature. The reaction followed yellow colored chromogen 
spectrophotometrically measured absorbance at 352 nm. Beer’s law was 
obeyed in the concentration range 2-12 µg/ml with molar absorptivity and 
Sandell’s sensitivity of 2.8339 x 104 L mol/cm and 0.001360 µg/cm2 per 
0.001 absorbance units, respectively 
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49. Dharamveer et al.
64 
developed for simultaneous estimation of DCN and 
Aceclofenac from tablet dosage form. 0.1M acidic methanol was used as 
solvent. First method, Simultaneous equation method, involves the 
measurement of absorbances at two wavelengths 256.0 nm (max of DCN) and 
276.0 nm (max of Aceclofenac), Second method is First order derivative 
spectroscopy, wavelength selected for quantitation were 250.0 nm for DCN 
(zero cross for Aceclofenac) and 256.8 nm for Aceclofenac (zero cross for 
DCN) and third method is Area under curve method, area under curve in the 
range of 251.0-261.0 nm (for DCN) and 271.0281.0 nm (for Aceclofenac) 
were selected for the analysis. The proposed methods were found to be rapid, 
specific, precise, accurate and can be successfully applied for the routine 
analysis of DCN and Aceclofenac in bulk and combined dosage form 
 
 
 
  Aim and plan of work 
 
Department of Pharmaceutics, Madras Medical College Page 35 
 
AIM OF WORK 
1. To formulate Diacerein microsponges using Eudragit RS 100 and Ethyl Cellulose 
polymers. 
2. To study the effect of Concentration of  External phase,  amount of  Internal phase 
and stirring rate on optimised formulation. 
3. To enclose Diacerein microsponges in Hard gelatin Capsules. 
 The objective of current work is to enhance the rate of solubility of the drug 
thus to augment bioavailability and to release the drug in a controlled manner to 
improve the efficacy and patient compliance. 
 
PLAN OF WORK 
 The present work was planned to carry out the Formulation and evaluation of  
Microsponges loaded with  Diacerein as model drug. 
The design of  work: 
I. Compatibility studies 
 Physical  compatibility study. 
 Chemical compatibility study. 
II. Preparation of Standard graph for Diacerein. 
III. Formulation and development  
 Preparation of  Diacerein microsponges by Quasi emulsion solvent 
diffusion method. 
 Evaluation of prepared microsponges. 
 Production yield. 
 Particle size determination. 
  Aim and plan of work 
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 Drug content. 
 Loading efficiency.   
 Surface topography. 
 
 Preformulation studies of optimized microsponge 
 Filling of Capsules 
IV. Evaluation of  Capsules 
 Uniformity of weight.  
 Disintegration test. 
 In-vitro release study of capsules. 
 Drug Content 
V. Evaluation of Optimised formulation 
 Effect of concentration of  External phase. 
 Effect of Concentration of  Internal phase. 
 Effect of  Stirring rate. 
VI. In-vitro anti-inflammatory activity. 
VII. Release kinetics of optimized formulation. 
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OSTEOARTHRITIS 65 
 Arthritis is a chronic degenerative disease that affects the joints of the body. 
Types include: Osteoarthritis, Rheumatoid arthritis, Psoriatic arthritis etc. 
   Osteoarthritis (wear and tear arthritis) is  the most common type of arthritis. It 
is associated with a breakdown of cartilage in joints and can occur in almost any 
joint in the body. It commonly occurs in the weight-bearing  joints of the 
hips, knees, and spine. It also affects the fingers, thumb, neck, and large toe. 
 Osteoarthritis  usually does not affect other joints unless previous injury , 
excessive stress or an underlying disorder of cartilage is involved. 
 It causes  the cartilage in a joint to become stiff and lose its elasticity, making it 
more susceptible to damage. Over time, the cartilage may wear away in some 
areas, greatly decreasing its ability to act as a shock absorber. As the cartilage 
deteriorates, tendons and ligaments stretch, causing pain. If the condition 
worsens, the bones could rub against each other. 
   RATIONALE FOR THE DRUG 
52, 78
 
 NSAIDs are a class of drugs used to treat inflammation and pain but their use 
increases the risk of upper gastrointestinal adverse effects and does not affect 
the underlying pathogenesis of articular diseases thus have minimal role in 
modifying disease course and improving quality of life. 
 DCN is a newly introduced Symptomatic drug for OA bone metabolism 
Pharmacological group. It is a semi- synthetic anthraquinone derivative 
extracted from certain plants. 
 In contrast to NSAIDs, DCN does not inhibit synthesis of prostaglandins, 
hence no gastro duodenal toxicity has been observed. Therefore, a safer 
symptomatic drug for OA. 
 DCN belongs to BCS class II (Low solubility and High permeability), thus 
selected to augment the bioavailability of the drug. 
 DCN is characterized by rapid clearance due its shorter half life and thus 
warrants the use of sustained release formulation for prolonged action to 
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improve its patient compliance. Therefore it is preferable to develop a method 
to deliver the drug in a sustained manner. 
RATIONALE OF DRUG DELIVERY SYSTEM  
3, 39,20
 
A set of reasons to select Microsponge drug delivery are as follows 
1. It offers extended release upto 12 hours i.e  A 25µm sphere can have a total 
pore length of about 10ft with a pore volume of about 1ml/g and can have up 
to 25,000 pores. This provides an extensive surface area for high entrapment. 
Because of entrapment and adsorption of actives onto the polymeric cage, the 
release of actives is prolonged. 
2. It enhances the rate of dissolution of poorly soluble drugs by entrapping them 
in their pores. As these pores are very small the drug released is reduced to 
microscopic particles. Therefore, decrease in particle size by micronization of 
such drugs result in an increase in dissolution rate and so the bioavailability. 
3. It is believed to contribute towards reduced side effects, better tolerance, 
improved stability, increased elegance along with formulation flexibility. 
4. They are stable over a pH range of 1 to 11, temperature upto 130o C. It also 
gives a higher load (50 to 60%) but still it is free flowing. 
5. One of the best feature of MDS is its Self-sterilizing. As the size of the pore 
diameter is smaller, the bacteria ranging from 0.007 to 0.2µm cannot penetrate 
into the tunnel structure of the microsponges. 
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OSTEOARTHRITIS 
65, 66
 
 Osteoarthritis (OA) represents failure of the diarthrodial (movable, synovial-
lined) joint. It is also erroneously called as degenerative joint disease. OA is primarily 
a disease of cartilage that reflects a failure of the chondrocyte to maintain proper 
balance between cartilage formation and destruction. This leads to loss of cartilage in 
the joint, local inflammation, pathologic changes in underlying bone and further 
damage to cartilage triggered by the affected bone. 
 According to the American College of Rheumatology, OA may be of;  
1. Idiopathic 
 i. Localized (spine, knee, hip, hands, feet, elbow, shoulder and other joints) 
 ii. Generalized (involving 3 or more joints) 
2. Secondary 
 i. Trauma 
 ii. Developmental and congenital diseases (dyplasia etc) 
 iii. Metabolic diseases (gout etc.) 
 iv. Endocrine disorders (diabetes, hypothyroidism etc.) 
 v. Calcium deposition diseases (pyrophosphate, hydroxyapatite etc.) 
 vi. Other bone and joint diseases (rheumatoid arthritis etc.) 
 vii. Neuropathic (Charcot) arthropathy 
 viii. Septic arthritis 
 
Epidemiology 
 OA is the most common joint disease of humans. Among the elderly, knee OA 
is the leading cause of chronic disability in developed countries. Some 100,000 people 
in the US are unable to walk independently from bed to bathroom because of OA of 
the knee or hip. 
 In older individuals, hip OA is more common in men, while OA of 
interphalangeal joints and the thumb base is more common in women. 
Similarly symptomatic knee OA is more common in women than in 
men. 
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 Racial differences exist in both the prevalence of OA and the pattern of 
joint involvement. The Chinese in Hong Kong have a lower incidence 
of hip OA than whites. OA is more frequent in native Americans than 
in whites. Interphalangeal joint OA and especially hip OA are much 
less common in South African blacks than in whites in the same 
population. 
 Age is the most powerful risk factor for OA. In a radiographic survey 
of women 45 years, only 2% had OA, between the ages of 45 and 64 
years, however, the prevalence was 30% and for those 65 years it was 
68%. 
 The prevalence of clinician diagnosed arthritis is estimated at 46 
million in the US and is projected to increase to nearly 67 million by 
2030 of which 25 million are expected to report arthritis related 
activity limitations. 
Incidence 
 The overall incidence of hip or knee OA is approximately 200 per 100,000 
person years. Approximately one half million symptomatic new cases of OA are 
estimated to occur annually in the US. 
 
Risk factors for OA 
 Age  
 Repetitive stress eg. Vocational 
 Female sex 
 Obesity 
 Race Congenital/ developmental defects 
 Genetic factors prior inflammatory joint disease 
 Major joint trauma 
 Metabolic/endocrine disorders 
Developmental stages of Osteoarthritis 
A. Destruction of the cartilage 
 Proteolytic damage to the cartilage matrix 
B. Inflammation of the synovial membrane 
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 Fibrillation and erosion of the cartilage surface and release of 
degradation products from the synovial fluid. 
C. Remodeling of subchondral bone 
 The synovial cells consume the degradation products. 
Production of inflammatory proteases and cytokines.
 
 
 
 
 
 
Fig No.5.2: Normal and OA 
knee joint 
 
Fig No.5.1: A Osteoarthritic joint 
Fig No.5.3:A cartilage eroded hip 
joint 
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Physiopathology of Osteoarthritis 
 The physiopathology of OA is not completely understood, but progress is 
being made. 
 Under normal conditions, the components of the cartilage matrix are gradually 
replaced. Chondrocytes are the cells responsible for this metabolism in which 
synthesis(anabolism) and destruction (catabolism) are balanced in a 
coordinated way. 
 When this process is altered, a series of changes occurs in the morphological 
and biomechanical characteristics of cartilage that make it fail to perform its 
function. 
 Protease inhibitors and anti-inflammatory cytokines participate in the anabolic 
process, where the final aims are the formation of the extracellular matrix and 
cell proliferation. 
 Pro-inflammatory cytokines and proteases participate in the catabolic process, 
which results in the destruction of the cartilage matrix and a reduction of cell 
proliferation. 
 
Signs and symptoms 
 Nearly all patients have pain in the affected joints, with the hands, knees, and 
hips being the most common locations with motion, but pain in late disease can 
occur with rest. 
o Joint stiffness resolves with motion; recurs with rest 
o Joint stiffness with or without joint enlargement 
o Crepitus, a crackling or grating sound heard with joint movement that is 
caused by irregularity of joint surfaces may be present. 
o Limited range of motion that may be accompanied by joint instability. 
o Late stage disease is associated with joint deformity 
 
 Diagnosis 
 In general, the disease can be detected because of its clinical and radiological 
signs. Some of the methods used to detect the clinical manifestations of Osteoarthritis 
include: 
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 Measuring pain using Huskisson’s visual analogue scale, WOMAC 
(Western Ontario and Mc Master Universities) Osteoarthritis Index 
 Measuring functional status 
 Joint fluid aspiraton 
 Radiology 
 Other tests include: Nuclear Magnetic Resonance(NMR), Ultrasound, 
Bone gammagram, CT scan, Arthroscopy 
 A system of Radiographic Grading of osteoarthritis is also used. It was 
developed by Kellgren and Lawrence and  key in current radiological 
assessment of osteoarthritis. 
 
Grades of Osteoarthritis 
Table No.: 5.1  Grades of OA 
Grade Classification Description 
0 Normal 
No characteristic symptoms of 
osteoarthritis 
1 Doubtful 
Indications of osteophytes 
Significance doubtful 
2 Minimal Definite osteophytes 
3 Moderate 
Moderate narrowing of joint 
space 
4 Severe 
Joint space very narrow, with 
subchondral bone sclerosis 
 
Treatment  
 The most common symptom associated with OA is pain, which leads to 
decreased function and motion. Pain relief is the primary objective of medication 
therapy. 
 
Non Pharmacologic measures 
 Non pharmacologic therapy is the foundation of the pharmaceutical care plan 
and should be initiated before or concurrently with pharmacologic therapy. 
 Reduction of joint loading 
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 Patellar taping 
 Thermal modalities 
 Exercise 
 Wedged insoles/orthoses 
 Diet 
Pharmacologic Therapy 
 Drug therapy for OA today is palliative, no pharmacologic agent has been 
shown to prevent, delay the progression of, or reverse the pathologic changes of OA 
in humans. It includes the following, 
 NSAID and Acetaminophen 
 Glucocorticoid injection 
 Intraarticular injection of hyaluronan 
 Opiods  
 Rubefacients/Capsaicin 
 Orthopedic surgery 
 Glucosamine, chondroitin sulfate 
 Cartilage regeneration 
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DIACEREIN
67-71
 
 Diacerein is a newly introduced one of the symptomatic slow acting drug for 
osteoarthritis. It is a semisynthetic anthraquinone derivative from certain plants. It 
belongs bone metabolism pharmacological group. 
 
PHYSICOCHEMICAL PROPERTIES 
Structure 
 
Synonym : Diacetyl rhein 
Description: A yellow fine powder. 
Molecular formula :C19H12O8 
Molecular weight: 368.3 
Chemical name: 9,10-dihydro-4,5-dihydroxy- 9,10- dioxo-2-anthranoic acid diacetate. 
Category: Anti Rheumatic agent 
Description : A yellow coloured powder 
Solubility: Soluble in DMSO 
Storage: Store at room temperature(25-30
o
c) 
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PHARMACOKINECTICS: 
Absorption: 
 Oral bioavailability of DCN is 35% to 56%. Concurrent intake of food delays 
the live to peak concentration from 2.4 hours to 5.2 hours but it is associated with a 
25% in absorption. Therefore DCN is given with food. 
Distribution: 
 Total protein binding is  99%  to plasma albumin and in a lesser percentage to 
lipoprotein and gamma immunoglobulin. It achieves synovial fluid concentration of 
0.3 to 3 mg/liter. 
Metabolism: 
 DCN is metabolised extensively (100%) in liver following oral dosing to the 
deacetylation active metabolite rhein, prior to entering systemic circulation . Major 
active metabolite include rhein glucoronide and rhein sulphate with half life being 7 
to 8 hours. 
Excretion: 
 Urinary excretion of DCN in the form of its metabolities has ranged from 35% 
to 60% with approximately 20% as free rhein and 80% as conjugates of rhein. 
PHARMACODYNAMICS: 
 Anti-osteoarthritic and a cartilage stimulating properties have been done in-
vitro and in animal studies. DCN and its metabolities have been shown to inhibit the 
production of interleukin-1 beta by human monocytes and the effects of the cytokines 
on chondrocytes in-vitro. They exerts chondroprotective effect in cultured articular 
cartilage and reduce severity of cartilage, bone synovial membrane damage in 
osteoarthritis. Therefore they appear to be some inhibitory effects in leucocyte 
migration and activation, contributing to the weak anti inflammatory activity of drug, 
studies indicate that DCN does not block the synthesis of  prostaglandin, the 
thromboxane and leukotrienes but may actually stimulate prostaglandin synthesis, 
especially PGF-2, a prostaglandin with cytoprotective effect in the gastric mucosa. 
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MECHANISM OF ACTION: 
 DCN in therapeutic doses inhibit the stimulation of interleukin-1 beta 
production and production of nitrous oxide. It also significantly reduces secretory of 
pathological changes of osteoarthritis compared to placebo and increases the 
expression of transforming growth factor (TGF)-beta 1 and (TGA)-beta 2, with 
potential cartilage repairing properties. DCN does not alter renal or platelet COX 
activity and may therefore be tolerated by patients with prostaglandin dependent renal 
function. 
INDICATION: 
 DCN is indicated for the treatment of osteoarthritis of hip and knee. 
DOSAGE AND ADMINISTRATION: 
 DCN should not be taken below 15 years of old as no clinical studies have 
been undertaken in the age group. The usual dosage of DCN is 50mg twice daily , 
after meals.  
SIDE EFFECTS: 
 Diarrhoea 
 Epigastric pain 
 Rashes 
 Pruritus 
 Nausea 
 Vomiting 
 Discolouration of urine 
 
CONTRAINDICATIONS: Pregnancy, Lactation, Hypersensitivity to anthraquinone 
derivatives. 
  
INTERACTIONS: 
 Absence of interaction with drugs such as  
 Warfarin 
 Tolbutamide 
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 Aspirin  
 Chlorpromazine 
 Indomethacin 
 
ADVERSE REACTIONS 
 The common reported adverse reaction was acceleration of the time of the 
intestinal transit (diarrhoea 37% of patients) few cases of abdominal pain have been 
describes, the medication of the dose in the initial periods of the treatment (2 to 4 hrs) 
has allowed to surpass or to diminish these adverse events. 
 Other adverse effects are urine discolouration in 14.4% cases and single case 
of hypokalemia, hepatotoxicity resulting into acute hepatitis and fatal toxic epidermal 
necrolysis(Lyell’s syndrome) 
 
AVAILABLE MARKETED PRODUCTS 
o Dyserin 
o Hilin 
o Rasin 
o Arcerin 
o Artifit 
o Ostogard 
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EUDRAGIT RS 100
72
 
1.Nonproprietary names 
BP:Ammonio methacrylate copolymer(Type B); USP-NF: Ammonio methacrylate 
2.Synonyms 
Eudragit, eastacryl,kollicoat MAE,Polymeric methacrylates, Acryl-EZE 
3.Chemical name 
Poly(ethyl acrylate,methyl methacrylate, trimethylammonioethyl methacrylate 
chloride). 
4.Structural formula  
 
5.Molecular weight is  >100000 
6.Description 
Eudragit RS100 are ammonio methacrylate copolymers synthesized from acrylic acid 
and methacrylic acid esters. It occurs as fine granules with a slight amine like odour. 
7.Solubility 
Eudragit RS100 is soluble in acetone, alcohols, dichloromethane,ethylacetate and are 
water insoluble. 
8.Functional category 
Film forming agent, tablet binder, tablet diluents 
9.Applications in Pharmaceutical formulation 
Eudragit RS100 is used to form water insoluble film coats for sustained release 
products. It is also used as binders in both aqueous and organic wet granulation 
processes. They may also be used in direct compression processes and form the 
matrix layers of transdermal delivery systems. It is used to control the release of an 
active substance from a tablet matrix.  
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ETHYL CELLULOSE
72
 
1 .Nonproprietary Names 
    BP: Ethylcellulose PhEur: Ethylcellulosum USPNF: Ethylcellulose 
2 .Synonyms  
    Aquacoat ECD; Aqualon; E462; Ethocel; Surelease. 
3 .Chemical Name and CAS Registry Number 
    Cellulose ethyl ether [9004-57-3] 
4 .Empirical Formula and Molecular Weight 
   Ethylcellulose with complete ethoxyl substitution (DS = 3) is     
C12H23O6(C12H22O5)nC12H23O5 where n can vary to provide a wide variety of 
molecular weights. Ethylcellulose, an ethyl ether of cellulose, is a long-chain polymer 
of b-anhydroglucose units joined together by acetal linkages. 
5 .Structural Formula 
 
6 .Functional Category 
   Coating agent; tablet binder; tablet filler; viscosity-increasing agent. 
7 .Description  
  Ethylcellulose is a tasteless, free-flowing, white to light tan colored powder. 
8. Solubility:  
        Ethylcellulose is practically in soluble in glycerine ,propyleneglycol, and water. 
Ethylcellulose that contains less than 46.5% of ethoxyl groups is freely soluble in 
chloroform, methyl acetate, and tetrahydrofuran, and in mixtures of aromatic 
hydrocarbons with ethanol (95%).  
9 .Applications in Pharmaceutical Formulation or Technology   
   Ethylcellulose is widely used in oral and topical pharmaceutical formulations. The 
main use of ethylcellulose in oral formulations is as a hydrophobic coating agent for 
tablets and granules.Ethylcellulose coatings are used to modify the release of a drug, 
to mask an unpleasant taste, or to improve the stability of a formulation.  
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POLYVINYL ALCOHOL
72
 
1 .Nonproprietary Names 
   PhEur: Poly(vinylis acetas) USP: Polyvinyl alcohol 
2 .Synonyms 
   Airvol; Alcotex; Elvanol; Gelvatol; Gohsenol; Lemol; Mowiol; Polyvinol; PVA; 
vinyl alcohol polymer. 
3 .Chemical Name and CAS Registry Number 
    Ethenol, homopolymer [9002-89-5] 
4 .Empirical Formula and Molecular Weight 
    (C2H4O)n 20000–200000 Polyvinyl alcohol is a water-soluble synthetic polymer 
represented by the formula (C2H4O)n. The value of n for commercially available 
materials lies between 500 and 5000, equivalent to a molecular weight range of 
approximately 20000–200000. 
5 .Structural Formula 
 
6 .Functional Category  
  Coating agent; lubricant; stabilizing agent; viscosity-increasing agent. 
7 .Description 
  Odourless, white to cream coloured granular powder 
8.Solubility 
   Soluble in water, slightly soluble in ethanol(95%), insoluble in organic solvents    
 9 .Applications in Pharmaceutical Formulation or Technology 
   Polyvinyl alcohol is used primarily in topical pharmaceutical and ophthalmic 
formulations. It is used as a stabilizing agent for emulsions (0.25–3.0% w/v). 
Polyvinyl alcohol is also used as a viscosity-increasing agent for viscous formulations 
such as ophthalmic products. It is used in artificial tears and contact lens solutions for 
lubrication purposes, in sustained-release formulations for oral administration, and in 
transdermal patches. Polyvinyl alcohol may be made into microspheres when mixed 
with a glutaraldehyde solution. 
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TRIETHYL CITRATE
72
 
1 .Nonproprietary Names 
  BP: Triethyl citrate PhEur: Triethylis citras USPNF: Triethyl citrate 
2 .Synonyms 
  Citric acid, ethyl ester; Citroflex 2; Citrofol AI; E1505; Hydagen CAT; TEC. 
3 .Chemical Name and CAS Registry Number  
 2-Hydroxy-1,2,3-propanetricarboxylic acid, triethyl ester [7793-0] 
4 .Empirical Formula and Molecular Weight 
   C12H20O7 and 276.29 
5 .Structural Formula 
 
6 .Functional Category 
   Plasticizer. 
7 .Applications in Pharmaceutical Formulation or Technology  
   Triethyl citrate and the related esters acetyl triethyl citrate, tributyl citrate, and 
acetyltributyl are used to plasticize polymers in formulated pharmaceutical coatings. 
The coating applications include capsules, tablets, beads, and granules for taste 
masking, immediate release, sustained release, and enteric formulations. Triethyl 
citrate is also used as a direct food additive for flavouring, for solvency, and as a 
surface active agent. 
8. Description 
  Triethyl citrate is a clear, odourless, practically colourless, oily liquid. 
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MAGNESIUM STEARATE
72
 
1 Nonproprietary Names 
  BP: Magnesium stearate JP: Magnesium stearate PhEur: Magnesii stearas USPNF: 
Magnesium stearate 
2 Synonyms 
  Magnesium octa decanoate; Octadecanoic acid, Magnesium salt; Stearic acid, 
Magnesium salt. 
3 Chemical Name and CAS Registry Number 
   Octadecanoic acid magnesium salt [557-04-0] 
4 Empirical Formula and Molecular Weight  
   C36H70MgO4  and 591.34 
5 Structural Formula 
 
  6 Functional Category  
   Tablet and capsule lubricant. 
7 Applications in Pharmaceutical Formulation or Technology  
   Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams. 
8.Solubility  
   Practically insoluble in ethanol, ethanol(95%),ether and water; slightly soluble in 
warm benzene and warm ethanol (95%). 
9. Description  
  Magnesium stearate is a very fine, light white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odour of stearic acid and a characteristic 
taste. The powder is greasy to the touch and readily adheres to the skin. 
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MATERIALS 
Table No. 8.1 The list of drug and excipient, their manufacturer and role in the 
present study  
INGREDIENTS MANUFACTURER/SUPPLIER 
ROLE IN 
FORMULATION 
Diacerein Madras Pharmaceuticals, Chennai Active ingredient 
Eudragit RS 100 Evonik India Pvt. Ltd, Mumbai Polymer 
Ethylcellulose Caplin Point, Puducherry Polymer 
Polyvinyl alcohol S D fine chem.. Ltd, Mumbai Stabilizing agent 
Triethyl citrate Himedia Laboratories Pvt. Ltd. Plasticizer 
Dichloromethane Chenchems Solvent 
Magnesium stearate Kniss laboratories, Chennai Lubricant 
Potassium dihydrogen 
phosphate 
Qualigens Reagent 
Sodium hydroxide Chenchems Reagent 
 
EQUIPMENTS USED FOR PREPARATION OF MICROSPONGES 
 Table No.8.2   Equipments used in the formulation and evaluation of 
microsponges. 
NAME OF THE EQUIPMENT MANUFACTURER/ SUPPLIER 
Electronic balance Asha Scientific Company, Mumbai. 
High speed homogenisor Remi electrotechnik, Vasai 
Hot air oven Mc Dalal, Chennai 
Optical Microscope 
Sigma Scientific Instrumentation, 
Chennai 
pH meter Mc Dalal, Chennai 
Dissolution apparatus Campbell electronics, Mumbai 
UV spectrophotometer Shimadzu, Japan 
FT-IR spectrophotometer Shimadzu, Japan 
SEM Analyser Hitachi, Japan 
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METHODOLOGY 
DRUG-EXCIPIENT COMPATIBILITY STUDY 
 The drug and excipients selected for the formulation are evaluated for physical 
and chemical compatibility studies. 
 
PHYSICAL COMPATIBILITY STUDY 
30 
  100mg each of powder drug, Polymer, PVA were weighed. Individual drug,    
polymer, PVA along with admixture of drug and excipients in airtight screw cap 
amber colored vials., kept at room temperature as well as at 40
0
C ± 2
o
C / 75% ± 5 % 
RH for 30 days.                                                                      
CHEMICAL COMPATIBILITY STUDY 
23
 
 Infrared spectroscopy was conducted using FT-IR spectrophotometer and the 
spectrum was recorded in the wave number region of 4000 to 400 cm
-1
. The 
procedure consisted of dispersing the sample (drug alone, mixture of drug and 
excipients and the optimized formulation) in Potassium bromide and compressed into 
discs by applying a pressure of 5 tons for 5 minutes in a hydraulic press. The pellet 
was placed in the light path and the spectrum was recorded.  
STANDARD CURVE FOR DIACEREIN 
45, 62
  
 10 mg of diacerein was weighed and transferred to 100 ml of volumetric flask. 
The drug was dissolved in 2 ml DMSO and the volume was made up to 100 ml using 
phosphate buffer pH 6.8 to obtain a stock solution of 100 μg/ml (stock solution I). 
One ml of this stock solution was again diluted with phosphate buffer pH 6.8 up to 10 
ml to obtain a solution of 10 μg/ml (stock solution II). From stock solution II of 2, 4, 
6, 8, 10 ml were transferred to a series of 10 ml volumetric flasks. The volume was 
made up with phosphate buffer pH 6.8. The absorbances of these solutions was 
measured at 258 nm against blank.  
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FORMULATION DEVELOPMENT 
Formulation of Diacerein Microsponges 
Diacerein microsponges were prepared by using Quasi emulsion solvent 
diffusion technique with Polymers like Eudragit RS 100 and Ethyl cellulose at 
different drug to polymer ratios.  
Procedure to formulate microsponges 
40
 
1. Internal phase:  Polymer (Eudragit RS 100/ Ethyl Cellulose) was dissolved in 
5ml of  dichloromethane. Diacerein was added and mixed well until it gets 
dissolved completely and to which triethyl citrate was added to facilitate 
plasticity. 
2. External phase: Accurately weighed PVA is added to distilled water  to form 
clear solution. 
3. The internal phase was added to external phase and stirred for 2 hours at room 
temperature. 
4. The mixture was filtered to separate microsponges and were dried in an air 
heated oven at 40
o
C for 12 hr  and stored for subsequent investigation. 
 
 
Fig. No.: 8.1   Formulation of microsponges
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Table No.:8.3   Composition of  Diacerein microsponges 
 
 
 
 
 
 
 
 
Ingredients M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 
Diacerein (mg) 200 400 600 800 1000 200 400 600 800 1000 
Eudragit RS 100 
(mg) 
200 200 200 200 200 - - - - - 
Ethyl cellulose 
(mg) 
- - - - - 200 200 200 200 200 
Polyvinyl alcohol 
(mg) 
200 200 200 200 200 200 200 200 200 200 
Triethyl citrate 
(ml) 
0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Dichloromethane 
(ml) 
5 5 5 5 5 5 5 5 5 5 
Distilled water 
(ml) 
100 100 100 100 100 100 100 100 100 100 
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Fig.No.8.2: SCHEMATIC PRESENTATION OF DIACEREIN 
MICROSPONGE CAPSULES 
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EVALUATION OF MICROSPONGES 
PRODUCTION YIELD
34
 
 Percentage yield can be determined by calculating the initial weight of raw 
materials and the finally obtained weight of microsponges. Percentage yield can be 
calculated by using the formula:   
                                   Practical yield  
      Production yield=       ----------------------   X 100  
           Theoretical yield 
LOADING EFFICIENCY 
27
 
 The microsponges was determined spectrophotometrically (λmax = 258 nm). 
A sample of DCN microsponges (100 mg) was dissolved dissolved in 100 ml of 
phosphate buffer (pH 6.8) and kept for overnight. The drug content was determined 
and expressed as actual drug content in microsponge. The loading efficiency (%) of 
the microsponges was calculated according to the following equation,   
                              Actual drug content in microsponges                 
Loading efficiency = ------------------------------------------------ X 100                                                      
                         Theoretical drug content 
 
PARTICLE SIZE ANALYSIS 
39
 
 Determination of the average particle size of  Diacerein loaded microsponges 
was determined with an optical microscope using a calibrated ocular and stage 
micrometer. A minute quantity of microsponges was spread on a clean glass slide 
with a drop of liquid paraffin and a cover slip is placed on it. The average particle size 
was calculated by measuring 100 particles of each batch.  
   dav = ∑ nd ∕ ∑n 
 Where, dav is the average diameter of particles (μm), n is number of particles 
per group, and d is the middle value (μm). 
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SURFACE MORPHOLOGY
 41
 
Scanning Electron Microscopy of optimized microsponge formulation was 
carried to determine the surface morphology. The sample was mounted directly onto 
the SEM sample holder using double sided sticking tape and images were recorded at 
different magnifications at acceleration voltage of 10 kV using scanning electron 
microscope. 
In-vitro DRUG RELEASE STUDY
24
 
 In-vitro release rate studies of microsponges were carried out by filling 
equivalent amount of microsponge in capsules placed in the basket containing 
phosphate buffer pH 6.8 was used as medium and rotated at 50 rpm. Samples was  
withdrawn and determined by spectrophotometrically at 258 nm. 
PREFORMULATION FOR CAPSULES 
FLOW PROPERTY MEASUREMENTS 
The flow properties of powders are critical for an efficient tabletting and 
capsule filling operation. A good flow of the powder or granules is necessary to 
assure efficient mixing and acceptable weight uniformity for the compressed tablet 
and capsules. The flow property measurements include bulk density, tapped density, 
angle of repose, compressibility index and Hausner’s ratio. The flow property 
measurements of microsponges are determined . 
a) BULK DENSITY (ρb)
73
 
 It is the ratio of total mass of powder to the bulk volume of powder. It 
was measured by pouring the weighed powder into a measuring cylinder and 
initial weight was noted. This initial volume was called the bulk volume. From 
this the bulk density was calculated according to the formula mentioned 
below. It is expressed in g/ml and is given by 
 ρb = M/ Vb  
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 Where, M and Vb are mass of powder and bulk volume of the powder 
respectively.    
b) TAPPED DENSITY(ρt)
73
 
 It is the ratio of weight of the powder to the tapped volume of powder. 
The powder was introduced into a measuring cylinder with the aid of funnel 
and tapped for 500 times on a wooden surface at a 2 sec interval and the 
volume attained is the tapped volume.  
 ρt = M / Vt   
             Where, M and Vt are mass and tapped volume of the powder respectively. It 
is expressed in g/ml. 
  
c) ANGLE OF REPOSE (θ)73 
The flow properties were characterized in terms of angle of repose, 
Carr’s index and Hausner’s ratio. For determination of angle of repose (θ), the 
drug and the blend were poured through the walls of a funnel, which was fixed 
at a position such that its lower tip was at a height of exactly 2.0 cm above 
hard surface. The drug or the blends were poured till the time when upper tip 
of the pile surface touched the lower tip of the funnel. Angle of repose was 
calculated using following equation.  
θ = tan-1(h/r)  
            Where, h = height of pile in cm; r = radius of pile in cm. 
d) CARR’S INDEX (OR) % COMPRESSIBILITY73 
 It indicates powder flow properties. It is measured for determining the 
relative importance of interparticulate interactions. It is expressed in 
percentage and is given by 
          ρt -ρb 
CI= -------------- X 100 
             ρt 
            Where, ρt and ρb are tapped density and bulk density respectively.  
MATERIALS AND METHODS 
 
Department of Pharmaceutics, Madras Medical College Page 62 
 
 
      e) HAUSNER’S RATIO73 
Hausner’s ratio is an indirect index of ease of powder flow. It is 
calculated by the following formula. 
 HR = ρt / ρb  
             Where, ρt and ρb are tapped density and bulk density respectively.   
f)  POROSITY (%)74 
Porosity is defined as the ratio of the void volume to the bulk volume 
of a powder packing. It is calculated  using true density value obtained 
from liquid displacement method. It  gives total porosity since the void 
space determined takes into account the intraparticle space i.e pores 
and cracks within the particles. It is also given as 
                               Bulk density 
                   ε     =   1 -  -------------------  X 100 
                    True density 
   
Table 8.4:  Angle of Repose, Compressibility Index and Hausner’s Ratio 
Flow property Angle of Repose(θ) 
Compressibility 
Index(%) 
Hausner’s Ratio 
Excellent 25-30 <10 1.00-1.11 
Good 31-35 11-15 1.12-1.18 
Fair 36-40 16-20 1.19-1.25 
Passable 41-45 21-25 1.26- 1.34 
Poor 46-55 26-31 1.35-1.45 
Very Poor 56-65 32-37 1.46-1.59 
Very very Poor >65 >38 >1.60 
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PREPARATION OF CAPSULE 
 The optimised microsponges were filled into “1” size capsule each containing 
100mg equivalent of DCN. 
Table No.:8.5   Preparation of  diacerein microsponge capsules 
 
 
 
EVALUATION OF CAPSULE 
UNIFORMITY OF WEIGHT 
75
 
Intact capsule were weighed. The capsule were opened without losing 
any part of the shell and contents were removed as completely as possible. The 
shell was washed with ether or other suitable solvent and the shell allowed to 
stand until the odour of the solvent was no longer detectable. The empty shell 
was weighed the procedure was repeated with a further 19 capsules. The 
average weight was determined. Not more than two of the individual weights 
deviate from the average weight by more than the percentage deviation shown 
in table 8.6 and none deviates by more than twice that percentage. 
Table No. 8.6: Uniformity of weight 
Average weight of  capsule contents Percentage deviation 
Less than 300mg 10 
300mg or more 7.5 
 
Optimized formulation 
Diacerein microsponges 
(mg) (equivalent to 
100mg) 
Magnesium stearate (mg) 
(3%) 
F5 150 4.5 
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DISINTEGRATION TEST 
75
 
This test determines whether capsules disintegrate within a prescribed time 
when placed in a liquid medium under the prescribed experimental conditions. 
 A capsule was placed in each of the six tubes of the apparatus and one 
disc was added to each tube. The time in minutes taken for complete 
disintegration of the capsule with no palpable mass remaining in the apparatus 
was measured. 
DRUG CONTENT
75
  
 Five capsules were selected randomly and the average weight was 
calculated. The powder is removed completely and equivalent amount of 
powder is made up to 100ml with phosphate buffer pH 6.8. 10ml of solution is 
diluted to 100ml using phosphate buffer pH 6.8 in separate standard flask. The 
absorbance of solution was recorded at 258nm. 
In-vitro DRUG RELEASE 
24
 
In-vitro release studies of microsponges were carried out by filling 
equivalent amount of microsponge along with lubricant in capsules and placed 
in the basket containing phosphate buffer pH 6.8 was used as medium and 
rotated at 50 rpm. Samples was withdrawn and determined by 
spectrophotometrically at 258 nm. 
 
Evaluation of optimized formulation 
Effect of stirring rate on microsponges:
20
 
 The effect of stirring rate on the formulated microsponges were examined at 
different stirring rates of 800,1000,1200 rpm . The results of stirring rates on the mean 
particle size, production yield, drug content and in-vitro drug release were studied . 
Effect of amount of  inner phase solvent on  microsponges: 
20
 
 The effect of inner phase solvent on the formulated microsponges were 
examined at different solvent amounts of 5,10,15 ml. The effect of inner phase solvent 
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on the mean particle size, production yield, drug content and in-vitro drug release was 
studied. 
Effect of external phase composition on microsponges: 
20
 
 The effect of external phase on the formulated microsponges were examined 
at different concentration of  PVA 0.2mg,0.3mg,0.4mg. The effect of external phase 
PVA on the mean particle size, production yield, drug content and in-vitro drug 
release was studied. 
In- vitro anti-inflammatory test: 
76
 
 1 ml of sample solution was withdrawn during in-vitro drug release study at 
every one hour interval, thereafter subjected to in-vitro anti-inflammatory analysis. 
For the purpose of control, equal volume of distilled water was used. To each reaction 
mixture, 1 ml of bovine albumin(1% in distilled water) was transferred and pH was 
adjusted to 6.3 by using small amount of 0.1 N HCl. Samples were incubated for 30 
min at 37
0
C in the dark followed by incubation at 57
0
C for 5 min. Reaction tubes 
were then cooled under running tap water and turbidity of all the samples were 
recorded spectrophotometrically at 660 nm. Percentage inhibition of  albumin 
denaturation was calculated by using  
Abs Control – Abs Sample 
Percentage inhibition        =  ------------------------------------   X    100 
     Abs Control 
RELEASE KINETICS OF THE OPTIMIZED FORMULATIONS
77
 
To study the in-vitro release kinetics of the optimized  formulation, data 
obtained from dissolution study were plotted in various kinetics models. 
1. Zero order equation :  The zero order release can be obtained by plotting 
cumulative % percentage drug released vs. time in hours                       
                                           C=K0t 
               Where,    K0= Zero order constant 
                   t= Time in hours   
2. First order equation:  
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The graph was plotted as log % cumulative drug remaining Vs time in hours.    
                        Log   C= log C0- Kt/2.303    
 Where,        C0= Initial concentration of drug ,  
                     K= First order, 
          t= Time in hours   
 
3. Higuchi kinetics: 
The graph was plotted with % cumulative drug released vs. square root of 
time.                  
                    Q = Kt ½   
Where ,    K= constant reflecting design variable system (differential 
rate constant)  
                 t= Time in hours .  
The drug release rate is inversely proportional to the square root of 
time. 
4. Hixon and Crowell erosion equation:  
To evaluate the drug release with changes in the surface area and the diameter 
of particles, the data were plotted using the Hixon and Crowell rate equation. The 
graph was plotted by cube root of % drug remaining vs. time in hours.     
          Q0
1/3 – Qt
1/3
 = KHC t      
Where ,     Qt= amount of drug released in time t,  
                  Q0= Initial Amount of drug ,  
                  KHC= Rate constant for Hixon Crowell equation   
5. Korsmeyer-Peppas equation: To evaluate the mechanism of drug release, it was 
further plotted in Korsmeyer-Peppas equation as log cumulative % of drug released 
Vs log time. 
                                                 Mt/Mα = Kt
n 
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                Where , Mt/Mα = Fraction of drug released at time t                           
        t = Release time                       
        K= Kinetics constant (Incorporating structural and geometric                                 
characteristics of the formulation)                      
        N= Diffusional exponent indicative of the mechanism of drug 
release.     
 
Table No. 8.7: Diffusion exponent and solute release mechanism for cylindrical 
shape Diffusion  
Diffusion coefficient Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45<n<0.89 Anamolous (non-fickian diffusion) 
0.89 Case II transport 
n>0.89 Super Case II transport 
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PHYSICAL COMPATIBILITY STUDY 
Table No.9.1: Physical compatibility study 
  S. 
No. 
Description and Conditions 
Drug & 
Excipient 
Initial 
Room temperature 
(in days) 
40
o  
C ± 2
o
C / 75 
% ± 5% RH 
(in days) 
10 20 30 10 20 30 
1 DCN 
Yellow coloured 
powder 
NC NC NC NC NC NC 
2 EUD 
White coloured 
granules 
NC NC NC NC NC NC 
3 EC 
White coloured 
powder 
NC NC NC NC NC NC 
4 PVA 
White coloured 
powder 
NC NC NC NC NC NC 
5 MS 
White coloured 
powder 
NC NC NC NC NC NC 
6 DCN+EUD 
Yellow coloured 
powder 
NC NC NC NC NC NC 
7 DCN+EC 
Yellow coloured 
powder 
NC NC NC NC NC NC 
8 DCN+PVA 
Yellow coloured 
powder 
NC NC NC NC NC NC 
9 DCN+MS 
Yellow coloured 
powder 
NC NC NC NC NC NC 
 
 The physical compatilibity study was performed. There was no change of 
colour. Therefore the drug and excipients are physically compatible with each other. 
The excipients which are compatible with the drug were selected for formulation. 
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FT-IR STUDY 
 Interaction between the drug and excipients used in the formulation was 
studied. The results are as follows 
 
 
 
Fig No.9.1 : FT-IR Of Diacerein 
 
Table No. 9.2: FT-IR Spectral interpretation of Diacerein 
Wave number(cm
-1
) Types of vibration 
1766.67 C=O Stretching 
2923.87 Ar-H  Stretching 
3440.76 O-H  Stretching 
1211.21 C-O  Stretching 
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Fig No.9.2 : FT-IR Of Diacerein and Eudragit RS 100 
 
 
Table No. 9.3: FT-IR Spectral interpretation of Diacerein and Eudragit RS 100 
Wave number(cm
-1
) Types of vibration 
1766.67 C=O Stretching 
2923.87 Ar-H  Stretching 
3440.76 O-H  Stretching 
1211.21 C-O  Stretching 
 
The peaks observed in the FT-IR spectrum showed no shift and no 
disappearance of characteristic peaks of drug. This suggests that there is no 
interaction between the drug and Eudragit RS 100.
79
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Fig No.9.3: FT-IR Of Diacerein and Ethyl Cellulose 
 
 
Table No. 9.4: FT-IR Spectral interpretation of Diacerein and Ethyl Cellulose 
Wave number(cm
-1
) Types of vibration 
1766.67 C=O Stretching 
2923.87 Ar-H  Stretching 
3440.76 O-H  Stretching 
1211.21 C-O  Stretching 
 
The peaks observed in the FT-IR spectrum showed no shift and no 
disappearance of characteristic peaks of drug. This suggests that there is no 
interaction between the drug and Ethyl Cellulose.
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Fig No. 9.4: FT-IR Of Diacerein and Polyvinyl Alcohol 
 
 
Table No. 9.5: FT-IR Spectral interpretation of Diacerein and Polyvinyl Alcohol 
Wave number(cm
-1
) Types of vibration 
1766.67 C=O Stretching 
2923.87 Ar-H  Stretching 
3440.76 O-H  Stretching 
1211.21 C-O  Stretching 
 
The peaks observed in the FT-IR spectrum showed no shift and no 
disappearance of characteristic peaks of drug. This suggests that there is no 
interaction between the drug and Polyvinyl Alcohol.
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Fig No. 9.5: FT-IR Of Diacerein and Magnesium Stearate 
 
 
Table No. 9.6: FT-IR Spectral interpretation of Diacerein and Magnesium 
Stearate. 
Wave number(cm
-1
) Types of vibration 
1766.67 C=O Stretching 
2923.87 Ar-H  Stretching 
3440.76 O-H  Stretching 
1211.21 C-O  Stretching 
 
The peaks observed in the FT-IR spectrum showed no shift and no 
disappearance of characteristic peaks of drug. This suggests that there is no 
interaction between the drug and Magnesium stearate.
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Fig No. 9.6: FT-IR Of Diacerein and powder blend 
 
Table No. 9.7: FT-IR Spectral interpretation of Diacerein and Powder blend 
(Eudragit RS 100) 
Wave number(cm
-1
) Types of vibration 
1766.67 C=O Stretching 
2923.87 Ar-H  Stretching 
3440.76 O-H  Stretching 
1211.21 C-O  Stretching 
 From the FT-IR spectra, it is clearly evident that the physical mixtrures 
of DCN with different excipients showed the presence of DCN characteristics bands 
at their same wave number. This indicates the absence of chemical interaction 
between the drug and the excipients.
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Fig No.9.7: FT-IR of Diacerein and powder blend 
 
Table No. 9.8: FT-IR Spectral interpretation of Diacerein and Powder 
blend(Ethyl cellulose) 
Wave number(cm
-1
) Types of vibration 
1766.67 C=O Stretching 
2923.87 Ar-H  Stretching 
3440.76 O-H  Stretching 
1211.21 C-O  Stretching 
 
From the FT-IR spectra, it is clearly evident that the physical mixtrures of 
DCN with different excipients showed the presence of DCN characteristics bands at 
their same wave number. This indicates the absence of chemical interaction between 
the drug and the excipients.
 79
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STANDARD GRAPH OF DIACEREIN
45
 
 Solutions of Diacerein in Phosphate buffer pH 6.8 were suitably diluted to 
give varying concentrations of 2-10µg/ml. The absorbances was measured at 258nm 
and the values are given in Table No.9.9 
Table No.9.9:  Absorbance of Diacerein in Phosphate buffer pH 6.8 
S.No. 
Concentration 
 (µg/ml) 
Absorbance 
1 0 0 
2 2 0.209±0.005 
3 4 0.407±0.012 
4 6 0.599±0.010 
5 8 0.805±0.013 
6 10 1.021±0.020 
 
 
Fig. No. 9.8:  Standard graph of diacerein in phosphate buffer pH 6.8 
 It was found that the solutions show linearity  (R
2
=0.999)in absorbance at a 
concentration of 2-10µg/ml and obeys Beer Lambert‟s law. 
 
 
 
 
 
 
y = 0.1012x + 0.0008 
R² = 0.9997 
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6 8 10 12
A
b
so
rb
an
ce
 
Concentration (µg/ml) 
Calibration curve of Diacerein 
RESULTS AND DISCUSSION 
 
Department of Pharmaceutics, Madras Medical College Page 77 
 
SCANNING ELECTRON MICROSCOPY 
 
Fig. No. 9.9:   Scanning Electron Microscopy of F5 
 
Fig. No. 9.10 :   Scanning Electron Microscopy of F9 
  The shape and surface morphology of optimized microsponges(F5,F9) 
was observed in SEM. It shows that the microsponges were spherical, porous and 
uniform.
21
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Fig. No.9.11:  A porous Microsponge 
EVALUATION OF MICROSPONGES 
PERCENTAGE YIELD 
Table No. 9.10:   Percentage yield of Diacerein microsponges 
Formulation 
code 
Theoretical yield  
( g) 
Practical yield  
(g) 
Percentage yield  
(%) 
F1 0.6 0.393 65.60 
F2 0.8 0.536 67.09 
F3 1 0.781 78.10 
F4 1.2 1.000 83.34 
F5 1.4 1.176 84.02 
F6 0.6 0.330 56.38 
F7 0.8 0.537 67.60 
F8 1 0.739 73.91 
F9 1.2 0.934 77.83 
F10 1.4 1.199 85.64 
 Microsponges were prepared and their Percentage yield was calculated. They 
were found to be in the range of 56.38% to 85.64%. It shows increasing drug:polymer 
ratio increased the percentage yield. The results correspond to earlier reports.
39
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LOADING EFFICIENCY 
Table No.9.11:    Percentage loading efficiency  
Formulation code Loading efficiency (%) 
F1 67.42 
F2 75.81 
F3 90.76 
F4 92.53 
F5 95.75 
F6 75.80 
F7 86.51 
F8 90.01 
F9 92.44 
F10 95.44 
 
 % Loading efficiency ranged from  67.42 to 95.75% . Highest loading 
efficiency was found for the formulation F5 and F10. This shows that increasing 
drug:polymer ratio increased loading efficiency. The results correspond to earlier 
reports
 39
 
 
 
 
Fig. No. 9.12  : Percentage loading efficiency 
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PARTICLE SIZE DISTRIBUTION BY OPTICAL MICROSCOPY 
 
Fig. No. 9.13 : Particle size distribution of F1 
 
Table No. 9.12 :    Particle size distribution of formulation F1 
 
                 n = 100          nd = 3915  
   
nd/n= 3915/100= 39.15µm 
 
 
 
 
 
0
10
20
30
40
0-15
15-30
30-45
45-60
60-75
75-90
%
 F
re
q
u
en
cy
 
Size range(µm) 
Size range   
(µm) 
Mean size (d) 
No. of 
particles(n) 
nd % Frequency 
0-15 7.5 10 75 10 
15-30 22.5 32 720 32 
30-45 37.5 20 750 20 
45-60 52.5 22 1155 22 
60-75 67.5 7 472.5 7 
75-90 82.5 9 742.5 9 
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Fig. No. 9.14:  Particle size distribution of F2 
 
 
Table No.9.13: Particle size distribution  of F2 
Size range  
(µm) 
Mean size (d) 
No. of 
particles (n) 
nd % frequency 
0-15 7.5 12 90 12 
15-30 22.5 34 765 34 
30-45 37.5 23 862.5 23 
45-60 52.5 20 1050 20 
60-75 67.5 5 337.5 5 
75-90 82.5 6 495 6 
                 n = 100           nd = 3600 
    
nd/n= 3600/100= 36µm 
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Fig. No. 9.15 :   Particle size distribution of F3 
 
 
Table No.9.14   Particle size distribution of F3 
Size range   
(µm) 
Mean size (d) No. of 
particles (n) 
nd % Frequency 
0-15 7.5 12 90 12 
15-30 22.5 41 922.5 41 
30-45 37.5 23 862.5 23 
45-60 52.5 13 682.5 13 
60-75 67.5 9 607.5 9 
75-90 82.5 2 165 2 
                       n=100            nd = 3330 
 
nd/n= 3330/100= 33.30µm 
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Fig. No.9.16:  Particle size distribution of F4 
 
 
Table No.9.15:   Particle size distribution of F4 
Size range 
 (µm) 
Mean size (d) No. of 
particles (n) 
nd % Frequency 
0-15 7.5 20 150 20 
15-30 22.5 42 945 42 
30-45 37.5 18 675 18 
45-60 52.5 15 787.5 15 
60-75 67.5 2 135 2 
75-90 82.5 3 247.5 3 
                                                           n=100                nd=2940 
 
nd/n= 2940/100= 29.40µm. 
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Fig. No.9.17:  Particle size distribution of F5 
 
 
Table No. 9.16:    Particle size distribution of F5 
Size range  
(in µm) 
Mean 
diameter (d) 
No. of 
particles (n) 
nd % Frequency 
0-15 7.5 22 165 22 
15-30 22.5 43 967.5 43 
30-45 37.5 20 750 20 
45-60 52.5 13 682.5 13 
60-75 67.5 1 67.5 1 
75-90 82.5 1 82.5 1 
                                                               n=100               nd= 2715 
     
nd/n= 2715/100= 27.15µm 
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Fig. No. 9.18: Particle size distribution of F6 
 
 
Table No.9.17:  Particle size distribution of F6 
Size range 
 (µm) 
Mean 
diameter (d) 
No. of 
particles (n) 
nd % Frequency 
0-15 7.5 0 0 0 
15-30 22.5 15 337.5 15 
30-45 37.5 27 1012.5 27 
45-60 52.5 32 1680 32 
60-75 67.5 18 1215 18 
75-90 82.5 7 577.5 7 
90-105 97.5 1 97.5 1 
                                                           n=100                 nd=4920 
 
nd/n= 4920/100= 49.20µm  
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Fig. No. 9.19:  Particle size distribution of F7 
 
 
Table No.9.18:   Particle size distribution of F7 
Size range  
(µm) 
Mean 
diameter (d) 
No. of 
particles (n) 
nd % Frequency 
0-15 7.5 6 45 6 
15-30 22.5 26 585 26 
30-45 37.5 21 787.5 21 
45-60 52.5 24 1260 24 
60-75 67.5 16 1080 16 
75-90 82.5 6 495 6 
90-105 97.5 1 97.5 1 
                                                           n=100              nd=4350 
     
nd/n=4350/100= 43.50µm 
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Fig. No.9.20:  Particle size distribution of F8 
 
 
Table No. 9.19:   Particle size distribution of F8 
Size range  
(µm) 
Mean 
diameter (d) 
No. of 
particles (n) 
nd % Frequency 
0-15 7.5 11 82.5 11 
15-30 22.5 37 832.5 37 
30-45 37.5 20 750 20 
45-60 52.5 24 1260 24 
60-75 67.5 5 337.5 5 
75-90 82.5 2 165 2 
90-105 97.5 1 97.5 1 
                                                           n=100                nd=3525 
     
nd/n=3525/100= 35.25µm 
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Fig. No.9.21:   Particle size distribution of F9 
 
 
Table No. 9.20:    Particle size distribution of F9 
Size range 
 (µm) 
Mean 
diameter (d) 
No. of 
particles (n) 
nd % Frequency 
0-15 7.5 11 82.5 11 
15-30 22.5 45 1012.5 45 
30-45 37.5 21 787.5 21 
45-60 52.5 12 630 12 
60-75 67.5 4 270 4 
75-90 82.5 3 247.5 3 
90-105 97.5 4 390 4 
                                                          n=100                   nd=3420 
   
nd/n=3420/100= 34.20µm 
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Fig. No. 9.22: Particle size distribution of F10 
 
 
Table No. 9.21: Particle size distribution of F10 
Size range 
 (µm) 
Mean 
diameter (d) 
No. of 
particles (n) 
nd % frequency 
0-15 7.5 18 13.5 18 
15-30 22.5 42 945 42 
30-45 37.5 22 825 22 
45-60 52.5 8 420 8 
60-75 67.5 7 472.5 7 
75-90 82.5 3 247.5 3 
                                                           n=100                 nd=3045 
    
nd/n= 3045/100= 30.45µm 
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AVERAGE PARTICLE SIZE OF MICROSPONGES 
 
Table No. 9.22:  Average particle size of microsponges 
 
S.No. Formulations 
Average particle size 
(µm) 
1 F1 39.15 
2 F2 36.00 
3 F3 33.30 
4 F4 29.40 
5 F5 27.15 
6 F6 49.20 
7 F7 43.50 
8 F8 35.25 
9 F9 34.20 
10 F10 30.45 
 
 
From the above results, it was found that particle size distribution was in the 
range of 27.15µm to 43.50µm. This reveals as drug: polymer increases the particle 
size went on decreasing.The results  corresponds to earlier reports
39
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In-vitro drug release of microsponges 
 
 The in-vitro release of various formulation are shown in Table No. 9.23 
 
Table No. 9.23:  In-vitro drug release of microsponges 
Time 
(Hrs) 
 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
1 05.54 05.90 06.08 06.80 06.78 03.94 05.00 05.54 06.78 06.78 
2 15.00 15.71 16.43 16.95 17.49 09.12 10.37 11.08 11.44 12.69 
3 23.44 24.68 25.23 26.29 27.72 12.72 16.84 21.81 23.24 24.67 
4 31.76 32.47 33.72 34.27 36.07 25.25 25.82 26.56 27.12 27.83 
5 40.10 41.36 44.40 44.59 45.50 28.95 30.23 30.97 33.13 33.85 
6 46.19 51.38 52.48 53.55 53.16 36.22 38.05 41.82 43.63 44.89 
7 54.57 56.63 57.03 57.77 58.14 45.13 45.71 46.67 46.71 48.87 
8 54.57 59.29 59.82 59.85 60.60 55.51 56.11 56.20 57.46 57.56 
9 64.64 67.06 65.50 67.30 70.18 64.89 65.65 66.98 68.27 67.78 
10 74.42 75.07 76.34 76.90 78.21 75.02 76.16 77.84 79.14 79.36 
11 78.39 79.02 80.30 80.88 82.72 79.53 80.48 81.63 82.05 84.58 
12 83.78 87.38 88.75 94.11 98.60 83.33 83.94 86.34 97.88 89.66 
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Fig. No. 9.23:  In-vitro release study of microsponges (F1-F5) 
 
 
 
 
Fig. No. 9.24:  In-vitro release study of microsponges (F6-F10) 
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In-vitro drug release study of optimized formulation (F5,F9) 
 
Table No.9.24:  In-vitro release of optimized formulation 
Time(in 
Hrs) 
% Drug release 
F5 F9 Marketed 
formulation 
1 6.9±0.30 6.36±0.71 42.74±0.05 
2 16.31±1.20 10.49±0.73 100.23±0.16 
3 25.7±1.75 21.87±1.68 - 
4 35.39±0.51 26.86±0.22 - 
5 46.02±0.62 32.45±0.95 - 
6 52.53±0.49 43.01±0.51 - 
7 57.70±2.27 45.80±0.67 - 
8 61.69±1.85 56.84±0.51 - 
9 69.80±1.21 67.34±0.74 - 
10 76.41±1.38 78.50±0.45 - 
11 85.89±5.32 84.2±3.21 - 
12 98.3±0.21 97.88±1.14 - 
     *Mean±SD (n=3) 
 
 
 
 
Fig. No. 9.25: In-vitro drug release study of optimized formulation 
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EVALUATION OF OPTIMIZED FORMULATIONS 
 
EFFECT OF STIRRING RATE 
 The effect of stirring rate of  F5 and F9 formulations was studied on % yield, 
mean particle size, % drug content & % drug release. The results are listed in table 
No.9.25 
Table No.9.25:  Stirring rate effect on F5 and F9 
F. 
Code 
 
 
Internal phase 
composition 
External phase 
composition 
Stirring 
rate 
(rpm) 
% 
yield 
Mean 
Particle 
Size 
(µm) 
 
% Drug 
content 
(% 
w/w) 
% Drug 
release 
Drug 
(g) 
Polymer 
(g) 
Solvent 
(ml) 
Water 
(ml) 
PVA(g)   
F5 
1 0.2 5 100 0.2 800 88.09 35.25 90.07 95.12 
1 0.2 5 100 0.2 1000 84.02 27.15 95.15 98.10 
1 0.2 5 100 0.2 1200 82.61 22.95 98.04 97.25 
 
F9 
 
0.8 0.2 5 100 0.2 800 85.00 41.55 87.29 97.88 
0.8 0.2 5 100 0.2 1000 77.87 34.20 90.44 91.61 
0.8 0.2 5 100 0.2 1200 70.81 26.25 94.38 93.11 
 
 
The results showed increasing stirring speed from 800 to 1200 rpm for both 
optimized formulations revealed decrease in % yield due to turbulence created within 
the external phase, polymer  then adhered to the stirrer. Upon increasing stirring speed 
reduction of mean particle size was observed as a vigorous, uniform, increased 
mechanical shear is imposed and this resulted in rapid dispersion of formed droplets 
which may have less chance of coalescing into bigger droplets. Drug content was 
increased on increasing stirring rate. The results corresponds to earlier reports.
 37,14,20
 
Drug release showed no particular pattern. 
 
 
RESULTS AND DISCUSSION 
 
Department of Pharmaceutics, Madras Medical College Page 95 
 
 
 
 
EFFECT OF CONCENTRATION OF  EXTERNAL PHASE  
 The effect of external phase of  F5 and F9 formulations was studied on % 
yield, mean particle size, % drug content & % drug release. The results are listed in 
table No.9.26 
Table No.9.26:  Effect of amount of External phase on F5 and F9 
F. 
Code 
 
 
Internal phase 
composition 
External phase 
composition 
Stirring 
rate 
(rpm) 
% 
yield 
Mean 
Particle 
Size 
(µm) 
% Drug 
Content 
( % 
w/w) 
%Drug 
release Drug 
(g) 
Polymer 
(g) 
Solvent 
(ml) 
Water 
(ml) 
PVA 
(g) 
 
F5 
1 0.2 5 100 0.2 1000 84.02 27.15 95.15 98.10 
1 0.2 5 100 0.3 1000 82.01 28.80 93.47 89.84 
1 0.2 5 100 0.4 1000 81.43 33.30 90.57 93.69 
 
F9 
0.8 0.2 5 100 0.2 1000 77.87 34.20 90.44 97.88 
0.8 0.2 5 100 0.3 1000 69.23 39.15 88.54 89.68 
0.8 0.2 5 100 0.4 1000 65.68 43.50 82.74 94.01 
 
It was observed that on increasing concentration of emulsifying agent on both 
formulations there was an increase in viscosity which resulted in larger emulsion 
droplets and finally in greater microsponges size. When the concentration of 
emulsifier was increased, the production yield and drug content decreased.
16
 Drug 
release showed no particular pattern. 
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EFFECT OF CONCENTRATION OF INTERNAL PHASE  
The effect of internal phase of  F5 and F9 formulations was studied on % yield, mean 
particle size, % drug content  & % drug release. The results are listed in table No.9.27 
Table No.9.27: Effect of concentration of Internal phase on F5 and F9 
 
 
F. 
Code 
 
 
Internal phase 
composition 
External phase 
composition Stirring 
rate 
(rpm) 
% 
yield 
Mean 
particle 
size 
(µm) 
% Drug 
content 
(% 
w/w) 
% 
Drug 
release 
Drug 
(g) 
Polymer 
(g) 
Solvent 
(ml) 
Water 
(ml) 
PVA  
(g) 
F5 
1 0.2 5 100 0.2 1000 84.02 29.85 95.15 98.10 
1 0.2 10 100 0.2 1000 82.12 27.15 91.04 90.31 
1 0.2 15 100 0.2 1000 79.44 24.15 85.51 93.02 
 
F9 
0.8 0.2 5 100 0.2 1000 87.87 34.20 90.44 97.88 
0.8 0.2 10 100 0.2 1000 82.16 28.20 88.60 87.14 
0.8 0.2 15 100 0.2 1000 74.66 25.34 85.47 92.38 
 
 It was found that by increasing the solvent volume the particle size of 
microsponges decreases. The particle size of microsponges were directly proportional 
to the viscosity of the dispersed phase. When the dispersed phase with higher 
viscosity was poured into the external phase, due to the higher viscosity of the internal 
phase, the globules of the formed emulsion could not be divided into smaller particles 
and bigger droplets were formed and mean particle size increased. When the amount 
of solvent was increased, drug content of microsponges decreased. This was probably 
due to the lower concentration of the drug in the high volume of solvent..
20,37  
There 
was no particular pattern followed for drug release. 
 
 
OPTIMISATION 
 Even on increasing drug: polymer ratio, amount of solvent, concentration of 
emulsifying agent and rate of stirring on optimized microsponges (F5, F9). F5  was 
optimised as the best formulation as it showed better results. 
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In-vitro anti-inflammatory activity 
Table No. 9.28: In-vitro anti-inflammatory activity of  F5 
Time (Hrs) 
% Inhibition 
Pure drug F5 
0.5 46.04 - 
1 68.35 30.93 
1.5 83.87 - 
2 - 37.01 
3 - 39.65 
4 - 45.94 
5 - 50.60 
6 - 53.54 
7 - 60.14 
8 - 64.60 
9 - 70.68 
10 - 74.34 
11 - 81.54 
12 - 83.77 
 
 
                     Fig No. 9.26 :  In-vitro anti-inflammatory activity 
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  Results of in-vitro anti-inflammatory activity by albumin denaturation 
method showed that the optimized formulation F5 inhibited approximately 80% 
within 12 hrs. F5 also exhibits a satisfactory dose dependent anti-inflammatory 
activity.
76
 
 
PREFORMULATION STUDIES OF THE DRUG AND  OPTIMIZED 
FORMULATION 
Table No.9.29: Preformulation parameters of drug and microsponges* 
F. 
Code 
Bulk density  
(g/ml) 
Tapped 
density        
(g/ml) 
Carr‟s Index 
(%) 
Hausner‟s 
ratio 
Angle of 
repose(θ) 
Porosity 
(%) 
Drug 0.299±0.002 0.478±0.001 37.44±0.002 1.564± 0.08 48
o57‟± 0.71 51 
F5 0.394±0.01 0.454±0.00 13.03±3.34 1.151±0.04 30
o03‟±1.61 73 
*Mean±SD (n=03) 
 The flow property of pure drug was found to be very poor. Good flow 
property  was observed for microsponges.
40
 
 
PREPARATION OF CAPSULE 
 The optimised microsponges were filled into “1” size capsule each containing 
100mg equivalent of DCN. 
POST FORMULATION STUDIES 
1.Uniformity of weight* 
Table No. 9.30: Uniformity of weight of Optimized capsule 
Formulation Average weight of Capsule (g) 
F5 0.154±0.0002 
*Mean±SD (n=20) 
  
The capsules comply with the official test for Uniformity of weight.
76
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2.Disintegration test 
Table No. 9.31: Disintegration test of Empty capsule 
Capsule Time (Min) 
Empty capsule 11 
The capsules comply with the official test for Disintegration test.
76 
 
3. Drug content* 
 The contents of  active ingredients in various formulations are given in the 
Table No. 
Table No. 9.32: Drug content of optimized formulation 
Formulation Drug content 
F5 98.65±0.804 
*Mean±SD (n=5) 
 The drug content was within limits i.e was not less than 90% and not more 
than 110%.(as per IP 2014).
76
 
4. In- vitro drug release study of F5 Capsule*  
Table No.:  9.33 In-vitro drug release study of  Capsule. 
S.No. Time(Hrs) 
% drug 
release 
1 1 6.87±0.09 
2 2 15.63±0.62 
3 3 24.69±0.18 
4 4 35.23±0.09 
5 5 45.74±0.61 
6 6 52.72±0.59 
7 7 57.30±0.80 
8 8 62.69±0.53 
9 9 75.79±0.36 
10 10 82.42±0.26 
11 11 94.76±0.80 
12 12 98.16±0.26 
           * Mean±SD (n=3) 
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Fig. No.9.27:  In-vitro release study of F5 capsule 
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RELEASE KINETICS OF THE OPTIMIZED FORMULATION 
 
Table No. 9.34:  Release kinetics of the optimised formulation (F5) 
Time 
(Hrs) 
Log 
time 
(Hrs) 
Sq. 
Root of 
time 
(Hrs) 
Cum % 
drug 
release 
Cum % 
drug 
remaining 
Log 
cum % 
drug 
release 
Log cum 
% drug 
remaining 
Cube root 
of cum % 
drug 
remaining 
0 -∞ 0 0 100 -∞ 2 4.64 
1 0 1 6.87 93.13 0.83 1.96 4.53 
2 0.30 1.41 15.63 84.37 1.19 1.92 4.38 
3 0.47 1.73 24.69 75.31 1.39 1.87 4.22 
4 0.60 2 35.23 64.77 1.54 1.81 4.01 
5 0.69 2.23 45.74 54.26 1.66 1.73 3.78 
6 0.77 2.44 52.72 47.28 1.72 1.67 3.61 
7 0.84 2.64 57.3 42.7 1.75 1.63 3.49 
8 0.90 2.82 62.69 37.31 1.79 1.57 3.34 
9 0.95 3 69.74 30.26 1.84 1.48 3.11 
10 1 3.16 75.42 24.58 1.87 1.39 2.90 
11 1.04 3.31 90.76 9.24 1.95 0.96 2.09 
12 1.07 3.46 98.16 1.84 1.99 0.26 1.22 
 
 
Fig. No. 9.28: A Plot of Zero order kinetics 
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Fig. No.9.29:  A Plot of First order kinetics 
 
 
         Fig. No. 9.30:  A Plot of Higuchi release kinetics 
 
                 Fig. No. 9.31:  A Plot of Korsemeyer- Peppas kinetics 
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      Fig. No. 9.32:  A Plot of Hixson- Crowell kinetics 
 The coefficient of determination (R
2
) was taken as criteria for choosing the 
most appropriate model. The R
2  
values of various models are in table No.9.35 
 
Table No. 9.35: R
2
 values of various kinetics models 
Kinetics models Coefficient of determination (R
2
) 
Zero order 0.991 
First order 0.738 
Higuchi 0.927 
Korsemeyer and Peppas 0.989 
Hixson Crowell 0.890 
  
The in-vitro drug release of the optimized formulation F5 was best explained 
by Zero order kinetics as the plots showed linearity (R
2
=0.991). This Zero order 
kinetics explains the controlled release of the prepared microsponges over the period 
of time.
23
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  Diacerein is a poorly soluble drug with short half life, thus selected as 
a model drug for MDDS to overcome these problems and to release the drug in a 
controlled manner. Diacerein is formulated as Microsponges  by Quasi emulsion 
solvent diffusion method using polymers  Eudragit RS 100 and Ethyl cellulose and 
finally enclosed in Capsules. 
 Compatibility studies were performed for drug and excipients 
 Physical compatibility study showed drug and excipients were physically 
compatible with each other. 
 Chemical compatibility study (FT-IR) was carried out. It revealed no 
interaction between the drug and excipients. 
 Standard graph was drawn for Diacerein and it was found that the solutions 
showed linearity  (R
2
=0.999) and obeyed Beer Lambert’s law. 
 Diacerein Microsponges were prepared using two polymers to determine 
which polymer retards the release better. 
 The in-vitro release was carried out for all the formulations. The formulation 
F5 (containing 5:1 drug: polymer (Eudragit RS 100) ratio) released 98.30% 
and  F9 ( containing 4:1 drug: polymer(Ethyl cellulose) ratio)at the end of 12
th  
hours. Therefore F5 and F9 were selected as optimized formulations. 
 The effect of stirring rate was studied on optimized formulations for 
determining production yield, drug content, mean particle diameter and drug 
release. The stirring rate increases production yield and drug content, while 
mean particle diameter decreased. No particular pattern was observed for drug 
release.  
 The effect of internal phase concentration was studied on optimized 
formulations for determining production yield, drug content, mean particle 
diameter and drug release. The internal phase concentration increases 
production yield, drug content and decreases mean particle diameter. F5 
showed a decrease in drug release with increase in solvent amount, but F9 
showed no particular pattern. 
SUMMARY AND CONCLUSION 
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 The effect of external phase concentration was studied on optimized 
formulations for determining production yield, drug content, mean particle 
diameter. The external phase concentration increases production yield, mean 
particle diameter but decreases  drug content. No particular pattern was 
followed for  drug release. 
 In-vitro anti-inflammatory activity by albumin denaturation method showed 
that the optimized formulation F5 inhibited approximately 80% within 12 hrs 
which clearly indicates that F5 also has exhibits a satisfactory dose dependent 
anti-inflammatory activity. 
 Even on increasing drug: polymer ratio, amount of solvent, concentration of 
emulsifying agent and rate of stirring on optimized microsponges (F5, F9). F5  
was optimised as the best formulation as it showed better results. 
 Preformulation study was carried out for drug and F5 microsponges. It 
revealed that  the flow property of pure drug was very poor, but the 
microsponges has good flow. 
 Post formulation parameters of capsules were evaluated and the results were 
found to comply with the official specifications. 
 The dissolution data of the optimized formulation were fitted to various 
kinetic models and the formulation F5 fitted best to Zero order kinetics. 
It is concluded that F5 formulation containing 5:1 drug:polymer ratio 
with Eudragit RS 100  produced Controlled release. 
Future scope 
1. In-vivo study. 
2. Pharmacokinetic and toxicity study. 
3. Stability studies. 
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